Radiopharmaceutical treatment methods and uses

Lu-PSMA I&T, a lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA complex, addresses the need for new therapies in prostate cancer by effectively targeting and treating tumors resistant to androgen receptor inhibitors, particularly in metastatic castration-resistant prostate cancer.

JP2024541595AInactive Publication Date: 2024-11-08POINT BIOPHARMA INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024532255
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2024541595000008
    Figure 2024541595000008
  • Figure 2024541595000009
    Figure 2024541595000009
  • Figure 2024541595000010
    Figure 2024541595000010
Patent Text Reader

Abstract

In one aspect, 177 Therapeutic uses, methods of treatment and kits comprising Lu-PSMA I&T are provided for subjects exhibiting progression of prostate cancer following administration of one or more androgen receptor inhibitors.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Application No. 63 / 283,999, filed November 29, 2021. The entire contents of U.S. Provisional Application No. 63 / 283,999 are incorporated herein by reference in their entirety.

[0002] FIELD OF THEINVENTION In one aspect, 177 Therapeutic uses and methods of treatment involving Lu-PSMA I&T are provided for subjects exhibiting prostate cancer progression following administration of one or more androgen receptor inhibitors. [Background technology]

[0003] Radiopharmaceuticals have been used in a variety of therapeutic and diagnostic applications. In particular, radiolabeled molecules are useful in treating a variety of malignancies.

[0004] Certain androgen receptor inhibitors have been utilized for the treatment of prostate cancer. However, these drugs are not always effective. See, for example, Watson et al., Nature Reviews Cancer, volume 15, pages 701-711 (2015).

[0005] It would therefore be desirable to have new anti-cancer therapies. It would be particularly desirable to have new therapies available for tumors that are not effectively treated with androgen receptor inhibitors. Summary of the Invention

[0006] Here, the inventors report the complex of lutetium-177 with EuK-Sub-kf-iodo-y-DOTAGA ( 177 This provides a new therapeutic use of Lu-PSMA I&T.

[0007] In certain aspects, a method is provided for treating a subject suffering from cancer, the method comprising: a) identifying a subject exhibiting cancer progression during treatment with one or more androgen receptor inhibitors; and b) administering to the identified subject an effective amount of a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

[0008] Also provided is a method for treating a subject suffering from cancer, comprising: a) administering to the subject a therapeutically effective amount of one or more androgen receptor inhibitors; b) identifying the subject as exhibiting progression of cancer after administration of the one or more androgen receptor inhibitors; and then c) administering to the identified subject an effective amount of a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

[0009] In a further aspect, a method for treating a subject suffering from prostate cancer is provided, comprising: a) identifying a subject who: i) exhibits progression of prostate cancer during or after treatment with one or more androgen receptor inhibitors; and ii) has not received chemotherapy prior to treatment with one or more androgen receptor inhibitors; and b) administering to the identified subject an amount of a lutetium-177 labeled PSMA targeted radioligand agent providing a dose of 4-10 Gbq, wherein the subject is administered at least four doses of the lutetium-177 labeled PSMA targeted radioligand agent with an inter-dosing interval of 4 weeks or longer. In a preferred aspect, the lutetium-177 labeled PSMA targeted radioligand agent is a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA, in particular 177 Lu-PSMA I&T.

[0010] In one aspect of the above method, the subject exhibits cancer progression during treatment with one or more of abitaterone, enzalutamide, apalutamide, darolutamide, cimetidine, orteronel, galeterone, ceviteronel, topirutamide, bicalutamide, fluamide, and / or nilutamide.

[0011] In a further aspect, the subject exhibits cancer progression during treatment with abitaterone, enzalutamide, apalutamide, and / or darolutamide.

[0012] In certain aspects, the subject has not received chemotherapy prior to administration of any androgen receptor inhibitor, and in addition to androgen receptor inhibitor therapy, the subject has received 177 The subject has not received chemotherapy prior to administration of Lu-PSMA I&T, i.e., the subject has not received any other chemotherapy (e.g., docetaxel-based chemotherapy or other radiopharmaceutical therapy) for the treatment of the subject's cancer.

[0013] Subjects may be treated with such agents for different times and under different conditions.Thus, in certain embodiments, subjects may show progression of cancer after treatment with one or more androgen receptor inhibitors for up to 1, 2, 3 or 4 weeks, or for longer periods such as up to 2, 3, 4, 5, 6 months or more.

[0014] In certain aspects, subjects may be evaluated for high or elevated prostate-specific membrane antigen (PSMA) expression compared to healthy subjects and identified as exhibiting high or elevated prostate-specific membrane antigen (PSMA) expression, and subjects identified as having elevated PSMA activity are administered a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA.

[0015] In certain embodiments, the methods and uses include imaging or other assessment of the subject's cancer, including assessment of PSMA expression, preferably prior to administration of one or more androgen receptor inhibitors and / or after administration of a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA ( 177Lu-PSMA I&T) may be administered prior to the administration of the antibody. Cancer assessment preferably includes imaging, such as SPECT or PET imaging, or immunohistochemistry / IHC or fluorescent in situ hybridization (FISH) imaging. To facilitate cancer analysis, 18 F or 68 A Ga agent (such as those disclosed in Example 2 below), or 64 An imaging agent, such as a Cu agent, can be administered to the subject.

[0016] In one aspect, a subject is identified for treatment if the subject exhibits 1) a PSMA expression standard uptake value of 15 or greater at one site of disease and / or 2) an SUVmax of greater than 10 at all measurable sites of disease.

[0017] In another embodiment, if the subject exhibits at least one positive lesion SUVmax greater than 10, the subject is identified for treatment.

[0018] In a further embodiment, a subject is identified for treatment if the subject has an elevated prostate specific antigen (PSA) level, e.g., a PSA level of 3 ng / mL, 4 ng / mL, 5 ng / mL, or 6 ng / mL or higher.

[0019] In certain embodiments, administration of one or more androgen receptor inhibitors is terminated prior to administration of a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

[0020] In certain embodiments, the subject suffers from cancer that expresses prostate specific membrane antigen (PSMA).In certain embodiments, the subject has prostate cancer.In certain embodiments, the subject suffers from metastatic castration-resistant prostate cancer (mCRPC).In further embodiments, the subject suffers from metastatic castration-resistant prostate cancer (mCRPC) with prostate specific membrane antigen (PSMA) avid lesion.

[0021] In one particular embodiment, the complex of lutetium-177 with EuK-Sub-kf-iodo-y-DOTAGA ( 177 Lu-PSMA I&T) is administered parenterally, such as intradermally, subcutaneously, intramuscularly, intraperitoneally and / or intravenously. 177 Lu-PSMA I&T is administered at a dose (single dose or daily dose) of about 1 GBq to about 15 GBq, or about 2 GBq to about 14 GBq, or about 3 or 4 GBq to about 10 or 12 GBq, or about 5 or 6 GBq to about 7, 8 or 9 GBq. A dose of 6.8 GBq + / - 10% per dose may be particularly preferred for various treatments. 177 Lu-PSMA I&T may be suitably administered under a variety of schedules, including multiple times per week, or once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks or more. 177 Lu-PSMA I&T administration may continue for up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 24, 26, 28, or 30 months.

[0022] 177 Lu-PSMA I&T is a lutetium ( 177 Lu) and EuK-Sub-kf-iodo-y-DOTAGA. The term "complex" as used herein refers to a bound or associated complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA ( 177 Lu-PSMA I&T), including chemical and physical variations that may be present 177 It generally refers to the union of Lu with the ligand EuK-Sub-kf-iodo-y-DOTAGA. 177 Lu-PSMA I&T and 177Lu-PNT2002 are used interchangeably herein and have the same meaning.

[0023] 177Lu-PSMA I&T has several possible stereoisomers, including R and S isomers of the carbons that are N-ring substituents of the tetraazacyclotetradecane portion of the compound. 177 References to Lu-PSMA I&T include all possible stereoisomers of each of these compounds, particularly both the R and S isomers shown above.

[0024] In certain embodiments, 177 A racemic mixture of Lu-PSMA I&T is utilized in the pharmaceutical compositions and methods of the present invention.

[0025] In another preferred embodiment, 177 An optically enriched mixture of Lu-PSMA I&T and EuK-Sub-kf-Iodo-y-DOTAGA is used in the methods and pharmaceutical compositions of the invention.

[0026] In certain preferred embodiments, including for use in the pharmaceutical compositions and methods of the invention, 177 An R isomer of Lu-PSMA I&T is provided, which can be represented by the following structure 2A: [ka]

[0027] In one aspect, the R isomer of structure 2A is substantially optically enriched for use in the methods and pharmaceutical compositions of the invention. 177 Lu-PSMA I&T, or an enantiomerically pure mixture of the R isomer of structure 2A, is generally preferred.

[0028] In another embodiment, 177 The S isomer of Lu-PSMA I&T is used in the pharmaceutical compositions and methods of the invention, which S isomer can be represented by the following structure 2B: [ka]

[0029] In one aspect, the S isomer of structure 2B is substantially optically enriched for use in the methods and pharmaceutical compositions of the invention. 177 Lu-PSMA I&T, or an enantiomerically pure mixture of the S isomer of structure 2B, is generally preferred.

[0030] For use in the method 177 The Lu-PSMA I&T preferably has high chemical or radiochemical purity, including greater than 95, 96, 97, 98, 99, 99.5, 99.6, 99.7, 99.8 or 99.9 percent radiochemical purity and / or the substantial absence of one or more prior impurities.

[0031] In a further embodiment, a treatment kit is provided. In a preferred embodiment, the kit may comprise: a) a pharmaceutical preparation of a lutetium-177 labeled PSMA-targeted radioligand agent suitable for intravenous administration to a patient in an amount sufficient to provide a dose of 4-10 Gbq; and b) a package insert containing instructions for use of the radioligand agent in treating a subject exhibiting prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has been previously treated with androgen receptor (AR) pathway inhibition, but who has not received taxane chemotherapy or for whom taxane chemotherapy is harmful (i.e., is ineligible for or averse to chemotherapy treatment options).

[0032] Also provided is the use of a lutetium-177 labeled PSMA targeted radioligand agent for treating a subject (such as a human) suffering from cancer, including prostate cancer, where a) the subject is identified as having i) a progression of prostate cancer during or after treatment with one or more androgen receptor inhibitors, and ii) having not received chemotherapy prior to treatment with one or more androgen receptor inhibitors, and b) the lutetium-177 labeled PSMA targeted radioligand agent is administered in an amount that provides a dose of 4 to 10 Gbq, the subject receiving at least four doses of the lutetium-177 labeled PSMA targeted radioligand agent with an inter-dosing interval of 4 weeks or longer. In a preferred embodiment, the lutetium-177 labeled PSMA targeted radioligand agent is a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA.

[0033] Other aspects of the invention are disclosed below.

[0034] definition As used herein, the terms "a," "an," "the," and similar terms as used in the context of the present invention (particularly in the context of the claims) are to be construed to encompass both the singular and the plural, unless otherwise specified herein or clearly contradicted by context.

[0035] "And / or" is used herein as a shorthand for the expression "and" describing a combination of items, and "or" describing items in alternative form.

[0036] Unless otherwise stated, structures depicted herein are also intended to include all stereochemical forms of the structure, i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.

[0037] The term "about" as used herein refers to an acceptable margin of error for a particular value, which depends, in part, on how the value is measured or determined. In certain embodiments, "about" as used herein will be understood by one of ordinary skill in the art to mean up to plus or minus 20% of the particular term. In further embodiments, "about" as used herein will be understood by one of ordinary skill in the art to mean up to plus or minus 10% of the particular term.

[0038] As used herein, the term "optically enriched" or "optically excess" refers to the presence of one or more non-racemic stereoisomeric centers in a molecule, and the configuration of at least one stereoisomeric center is predominantly one stereoisomeric configuration (R or S). For example, one stereoisomeric center in a molecule, typically a carbon atom, may have more than 50 or 55% by weight (based on the total weight of the compound) of its bonded atoms arranged in space in the (R) configuration. Alternatively, more than 50% by weight (based on the total weight of the compound) may be arranged in space in the (S) configuration. More preferably, the molecule or its stereoisomeric center is substantially optically enriched, and even more preferably, substantially enantiomerically pure.

[0039] As used herein, the term "substantially optically enriched" or "substantial optical excess", when referring to a stereoisomer or stereoisomeric center, indicates that at least about 60% by weight (based on the total weight of the compounds), preferably about 70% by weight (based on the total weight of the compounds), more preferably about 80% by weight (based on the total weight of the compounds), even more preferably about 90% by weight (based on the total weight of the compounds) of one stereoisomer or one stereoisomeric center configuration predominates in the mixture, with at least about 95% by weight (based on the total weight of the compounds) of one stereoisomer or one stereoisomeric center configuration being even more preferred. In some preferred embodiments, the compounds are "substantially enantiomerically pure", i.e., at least about 97.5% by weight (based on the total weight of the compounds), more preferably about 99% by weight (based on the total weight of the compounds), even more preferably about 99.5% by weight (based on the total weight of the compounds) of one stereoisomeric configuration predominating.

[0040] As used herein, the term "substantially pure" means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard analytical methods such as thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and mass spectrometry (MS), or sufficiently pure that further purification does not detectably alter the physical and chemical properties, or the biological and pharmacological properties, such as enzymatic and biological activity, of the substance. In certain embodiments, "substantially pure" refers to a collection of molecules in which at least about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 98%, about 98.5%, about 99%, about 99.5%, or about 99.9% or more of the molecules are a single compound, including a racemic mixture or a single stereoisomer thereof, as determined by standard analytical methods.

[0041] As used herein, unless otherwise specified, the terms "treat", "treating" and "treatment" refer to the eradication or amelioration of a disease, disorder or condition, or one or more symptoms associated with a disease, disorder or condition. In certain embodiments, the terms refer to minimizing the progression or worsening of such a disease, disorder or condition resulting from administration of a formulation of the invention to a patient / animal having such a disease, disorder or condition. In some embodiments, these terms refer to administration of a formulation provided herein after the onset of symptoms of a particular disease, disorder or condition. The terms "treat", "treating", "treatment" and the like, as used herein, encompass the treatment of a disease, disorder or condition in a subject, e.g., a mammal, and include at least one of: (i) inhibiting the disease, disorder or condition, i.e., partially or completely halting its progression; (ii) alleviating the disease, disorder or condition, i.e., causing regression of the symptoms of the disease, disorder or condition or improving the symptoms of the disease, disorder or condition; and (iii) reversing or regressing the disease, disorder or condition, preferably eliminating or curing the disease, disorder or condition. In certain embodiments, the terms "treat", "treating", "treatment", and the like encompass treatment of a disease, disorder, or condition in a mammal, e.g., a primate, e.g., a human, including at least one of (i), (ii), and (iii) above. Adjustments for age, weight, general health, sex, diet, time of administration, drug interactions, and severity of the condition may be necessary as known in the art and are ascertainable with routine experimentation by one of ordinary skill in the art based on the invention described herein.

[0042] As used herein, the terms "subject" and "patient" are used interchangeably. The terms "subject" and "patient" refer to animals such as mammals, including non-primates (e.g., cows, pigs, horses, sheep, rabbits, guinea pigs, rats, cats, dogs, and mice) and primates (e.g., monkeys, chimpanzees, and humans). In certain embodiments, the subject is a human. [Brief description of the drawings]

[0043] [Figure 1] Patient demographics and baseline characteristics of the safety analysis population (n=27). [Diagram 2] Treatment exposure in the safety analysis population (n=27). [Diagram 3] Kaplan-Meier curves for radiological progression-free survival. rPFS follow-up was calculated for all enrolled participants as the time in months from the date of enrollment to the date of the last available imaging (conventional) before the data cutoff. [Figure 4] Vignette of a participant in complete remission. [Diagram 5] Total incidence of treatment-emergent adverse events (TEAEs), all grades. [Figure 6A] Dosing technique. (6A) Gravity method [Figure 6B] Administration techniques. (6B) Pump method using a vial. [Figure 6C] Administration techniques. (6C) Syringe pump method. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0044] In one preferred embodiment, we now provide a method for the treatment of human / patients suffering from prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC).

[0045] More specifically, patients with prostate cancer, including mCRPC, 177 To identify and select patients for treatment with Lu-PSMA I&T, they may then undergo a prostate-specific membrane antigen (PSMA)-based assay, such as PET or other imaging. 177 Lu-PSMA I&T may be administered to select patients, including following androgen receptor-axis-targeted therapy (ARAT).

[0046] In one aspect, high PSMA avidity or expression in a patient / animal may be assessed by 1) or 2) below. 1) For patients with measurable disease (using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria): i) a threshold standard uptake value (SUV)max of 15 or greater at one site of disease, and ii) SUVmax >10 in all measurable disease sites. 2) For patients / animals without measurable disease, at least one positive lesion SUVmax greater than 10.

[0047] As referred to herein, SUV (Standard Uptake Value) is 68 Ga or 18 It may be evaluated by known procedures such as administering a F compound or other tracer and imaging the subject (e.g., PET, PET / CT). For subject SUV analysis and value determination, see Dietlein et al. Mol. Imaging Biol. 2015; 17(4): 575-584. For subject SUV (including SUVmax) analysis and value determination, which can be used to determine the SUV and SUVmax referred to herein, see also Giesel et al., J Nucl Med. 2018; 59(7): 1076-1080.

[0048] 177 Lu-PSMA I&T 177 Lu-PSMA I&T (including structures 2A and / or 2B below) 177 Lu (lutetium-177) or 177 It can be prepared by complexing or incorporating its halide, such as LuCl3, into EuK-Sub-kf-Iodo-y-DOTAGA (structures 1A and / or 1B below).

[0049] [ka]

[0050] The IUPAC designation for structure 2A is lutetate(5-)-177Lu,[N-[(4S)-4-(carboxy-KO)-4-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-KN1,KN4,KN7,KN10]-1-oxobutyl]-3-iodo-D-tyrosyl-D-phenylalanyl-N6-[8-[[(5S)-5-carboxy-5-[[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]amino]pentyl]amino]-1,8-dioxooctyl]-D-lysinate(8-)]-, hydrogen (1:5).

[0051] [ka]

[0052] The IUPAC designation of compound 2B is lutetate(5-)-177Lu,N-[(4R)-4-(carboxy-KO)-4-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-KN1,KN4,KN7,KN10]-1-oxobutyl]-3-iodo-D-tyrosyl-D-phenylalanyl-N6-[8-[[(5S)-5-carboxy-5-[[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]amino]pentyl]amino]-1,8-dioxooctyl]-D-lysinate(8-)]-, hydrogen (1:5).

[0053] [ka]

[0054] The S isomer of structure 1A has the IUPAC name N-[(4S)-4-(carboxy-KO)-4-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-KN1,KN4,KN7,KN10]-1-oxobutyl]-3-iodo-D-tyrosyl-D-phenylalanyl-N6-[8-[[(5S)-5-carboxy-5-[[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]amino]pentyl]amino]-1,8-dioxooctyl]-D-lysinate(8-)]-, hydrogen (1:5).

[0055] [ka]

[0056] The R isomer of structure 1B has the IUPAC name of [N-[(4R)-4-(carboxy-KO)-4-[4,7,10-tris[(carboxy-KO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-KN1,KN4,KN7,KN10]-1-oxobutyl]-3-iodo-D-tyrosyl-D-phenylalanyl-N6-[8-[[(5S)-5-carboxy-5-[[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]amino]pentyl]amino]-1,8-dioxooctyl]-D-lysinate(8-)]-, hydrogen (1:5).

[0057] Structures 1A and / or 1B may be suitably formed as described in Weineisen et al. J Nucl Med 2015; 56: 1169-1176; and Chatalic, Theranostics, 6(6), 849-861 (2016). 177To provide optically enriched or substantially optically enriched or enantiomerically pure samples of Lu-PSMA I&T, the corresponding optical isomers of EuK-Sub-kf-iodo-y-DOTAGA may be used in the incorporation reaction. That is, a compound of structure 1A may be reacted with lutetium-177 to give the S-isomer complex of structure 2A, and a compound of structure 1B may be reacted with lutetium-177 to give the R-isomer complex of structure 2B. Structures 1A and / or 1B may also be obtained from piCHEM (RaabaGrambach, Austria). Optically enriched mixtures of structures 1A and / or 1B may be conveniently prepared by the use of optically enriched precursors (reagents) and / or separation of the optical isomers by suitable optically active reagents such as optically active salts.

[0058] As referred to herein 177 Lu-PSMA I&T is a compound having the above structures 2A and / or 2B, as well as lutetium ( 177 Lu) and other complexes of EuK-Sub-kf-iodo-y-DOTAGA. For example, 177 References to Lu-PSMA I&T generally correspond to structures 2A and / or 2B, 177 These include compounds in which Lu is substantially complexed with other portions or moieties of the EuK-Sub-kf-Iodo-y-DOTAGA molecule other than those shown in structures 2A and 2B above (such as one or more other nitrogens). 177 Reference to Lu-PSMA I&T may also include stereoisomers other than those shown in structures 1A, 1B, 2A, and 2B above, although the stereoisomers shown in structures 1A, 1B, 2A, and 2B, particularly structures 1A and 2A, are preferred.

[0059] 177 To synthesize Lu-PSMA I&T, lutetium-177 ( 177 Lu) can be mixed with EuK-Sub-kf-iodo-y-DOTAGA. 177Lu may suitably be carrier-added or, more preferably, non-carrier-added (nca) lutetium-177. To promote incorporation (e.g., complexation, including chelation) of lutetium-177 by the EuK-Sub-kf-Iodo-y-DOTAGA compound, the mixture of compounds is preferably heat-treated.

[0060] Pharmaceutical Compositions 177 Lu-PSMA I&T is suitably administered to a subject in an aqueous composition comprising 1) a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA, and 2) one or more stabilizer compounds, such as one or more ascorbate compounds. Preferably, the radiochemical purity of the composition is at least 95%, 96%, 97%, 95% or 99%, and the composition is maintained at or below 30° C. for 3, 4 or 5 days or longer after preparation of the composition.

[0061] In certain preferred embodiments, the pharmaceutical composition contains no unchelated lutetium-177 in an amount of 2, 1.5, 1.0 or 0.5% by weight or less based on the total weight of the pharmaceutical composition, as can be determined by radiometric detection (including HPLC radiometric detection), and the composition is maintained at or below 30° C., and such purity levels are exhibited for 3, 4 or 5 days or longer after preparation of the composition.

[0062] In further preferred embodiments, the pharmaceutical composition is free of radiochemical impurities in an amount of less than or equal to 5, 4, 3.5, 3, 2.5, 2, 1.5, 1 or 0.5% by weight based on the total weight of the pharmaceutical composition, as can be determined by radiometric detection (including HPLC radiometric detection), and the composition is maintained at or below 30° C., and such purity levels are exhibited for 3, 4 or 5 days or longer after preparation of the composition.

[0063] In still further preferred embodiments, the pharmaceutical composition is free of chemical impurities in an amount of 5, 4, 3, 2, 1 or 0.5% by weight or less based on the total weight of the pharmaceutical composition, as can be determined by chromatography or other methods, including HPLC or HPLC / UV analysis, and the composition is maintained at or below 30° C., and such purity levels are exhibited for 3, 4 or 5 days or longer after preparation of the composition.

[0064] In still further preferred embodiments, the pharmaceutical composition is 1) free of unchelated lutetium-177 in an amount of 2, 1.5, 1.0 or 0.5% by weight or less (as may be determined by radiometric detection (including HPLC radiometric detection)); 2) free of radiochemical impurities in an amount of 5, 4, 3.5, 3, 2.5, 2, 1.5, 1 or 0.5% by weight or less (as may be determined by radiometric detection (including HPLC radiometric detection)); and 3) free of chemical impurities in an amount of 5, 4, 3, 2, 1 or 0.5% by weight or less (as may be determined by HPLC / UV analysis), all weight percentages being based on the total weight of the pharmaceutical composition, and the composition is maintained at or below 30° C., and such purity levels are exhibited for 3, 4 or 5 days or more after preparation of the composition.

[0065] In certain embodiments, the pharmaceutical composition is formulated for parenteral administration, such as intravenous, intramuscular, intradermal, subcutaneous, intrathecal or intraperitoneal administration. For example, the pharmaceutical composition is formulated for intravenous, intramuscular, subcutaneous or intradermal injection. In a preferred embodiment, the pharmaceutical composition is formulated for intravenous administration. In an exemplary embodiment, the pharmaceutical composition may be administered in the form of an aqueous pharmaceutical solution.

[0066] Due to the radioactive nature of the drug composition, injection and / or infusion of the drug into a patient typically requires certain additional precautions to avoid exposing the health care provider to radiation or contaminating the infusion facility. In certain embodiments, the pharmaceutical composition is provided in a vial and injected intravenously, such as using a disposable syringe, optionally with a syringe shield attached in the case of handheld infusion administration. In such cases, a syringe with a syringe shield and a disposable sterile needle is used to withdraw the desired radioactive dose from the vial, and the pharmaceutical composition is administered by slow intravenous infusion (1-20 min, more preferably about 10 min) either manually or with a syringe pump (FIG. 6C). A three-way stopcock can be optionally used to allow switching between pre-administration saline wash and injection of the drug composition, respectively.

[0067] Figures 6A and 6B illustrate other methods for intravenous injection directly from the vial in which the drug composition is provided. For example, as shown in Figure 6A, the drug composition can be administered using a gravity feed technique in which saline (as shown, or other pharma- ceutically acceptable injectable buffer) is fed into the vial from a higher position by a short needle and catheter during injection. A short needle connected to saline or other injection fluid is placed in the vial, but does not contact the solution of the drug composition in the vial. A long needle is inserted and pushed into the vial so as to be in fluid communication with the drug composition. In other embodiments, as shown in Figure 6B, the short needle is instead a vented needle, and the long needle is connected to an infusion pump that pumps the drug composition from the vial into the patient being injected.

[0068] Certain embodiments of the packaged pharmaceutical kits of the invention include instructions including one or more of the above techniques, i.e., instructions for intravenous injection (manual or pumped), gravity-fed infusion, and / or infusion pumps.

[0069] In certain embodiments, the packaged pharmaceutical kit includes a disposable syringe, more preferably a disposable syringe with a syringe radiation shield, such as made of lead or tungsten.

[0070] In certain embodiments, the pharmaceutical composition is an aqueous solution, dispersion, or other mixture, such as for injection; 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Lu-PSMA I&T) and preferably one or more ascorbate compounds. In a further preferred embodiment, the pharmaceutical composition is an aqueous solution, dispersion, or other mixture, such as for injection, comprising: 1) 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Lu-PSMA I&T) and preferably one or more ascorbate compounds and one or more gentisate compounds.

[0071] In certain preferred embodiments, an aqueous pharmaceutical solution, dispersion or mixture may be utilized that comprises 1) a complex of Lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA, and 2) at least one stabilizer compound capable of inhibiting radiolytic degradation of the composition, preferably during storage after preparation of the complex. 177 The Lu-PSMA I&T is suitably present at a concentration that provides a volumetric radioactivity of at least 100 MBq / mL, preferably at least 250, 500, 750 or 1000 MBq / mL within 1, 2, 3, 4 or 5 days after preparation. 177 The Lu-PSMA I&T is present at a concentration that provides a volumetric radioactivity of 100-1000 MBq / mL, preferably up to about 250, 500, 750 or 1000 MBq / mL within 1, 2, 3, 4 or 5 days after preparation.

[0072] In certain embodiments, the aqueous medical formulation has a shelf life of at least 24 hours at or below about 30° C., at least 48 hours at or below about 30° C., at least 72 hours at or below 30° C., or 24 to 120 hours at or below 30° C., 24 to 96 hours at or below 30° C., 24 to 84 hours at or below 30° C., or 24 to 72 hours at or below 30° C., particularly a shelf life of at least 72 hours at or below 30° C. In further specific embodiments, the aqueous medical formulation has a shelf life of at least 96 hours (or 4 days) at or below about 30° C., or the aqueous medical formulation has a shelf life of at least 120 hours (or 5 days) at or below about 30° C., or the aqueous medical formulation has a shelf life of at least 144 hours (or 6 days) at or below about 30° C.

[0073] In a particularly preferred embodiment, 177 Lu-PSMA I&T is provided as a sterile solution for intravenous use. 177 The Lu-PSMA I&T solution may suitably be clear, colourless to slightly yellow. Single dose vials suitably contain 6.8+ / -10% GBq of Lu-PSMA I&T solution, calibrated for example 1, 2, 3, 4, 5 or 6 days or more after the date of manufacture. 177 The Lu-PSMA I&T is contained in 10-14 mL formulated with one or more radioprotectants and may include a buffer. The pH range of the solution is preferably 5.0-7.0. As discussed, the radioprotectants or stabilizers may be one or more ascorbate compounds, optionally together with one or more gentisate compounds. 177 Lu-PSMA I&T also can be administered in multiple doses, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more doses. 177 It may be provided in a multi-dose format or packaging, such as a multi-dose vial containing Lu-PSMA I&T.

[0074] Preferred for administration to a subject 177 Lu-PSMA I&T compositions are also disclosed in U.S. Pat. No. 11,129,921 and U.S. Pat. No. 11,491,246.

[0075] Treatment method As discussed, 177 Lu-PSMA I&T (comprising structures 2A and / or 2B above) is used to treat cancers, including those that express PSMA.

[0076] As discussed, in one embodiment, a method for treating a subject suffering from prostate cancer is provided, comprising: a) identifying a subject who shows progression of prostate cancer during or after treatment with one or more androgen receptor inhibitors, the subject having not undergone chemotherapy prior to treatment with one or more androgen receptor inhibitors; and b) administering to the identified subject an amount of lutetium-177 labeled PSMA-targeting radioligand agent that provides a dose of 4-10 Gbq, the subject being administered at least four doses of the lutetium-177 labeled PSMA-targeting radioligand agent with an interval of four weeks or longer between doses. In a preferred embodiment, the lutetium-177 labeled PSMA-targeting radioligand agent is a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA.

[0077] In certain embodiments, 177 Lu-PSMA I&T (comprising structures 2A and / or 2B above) is used to treat prostate cancer, e.g., non-metastatic and metastatic prostate cancer, including hormone-sensitive prostate cancer, castration-resistant prostate cancer (CRPC) and drug-resistant prostate cancer, particularly anti-androgen (e.g., abitaterone, enzalutamide, apalutamide and / or darolutamide) resistant prostate cancer.

[0078] In various ways, 177Lu-PSMA I&T (comprising structures 2A and / or 2B above) can be administered to a subject, such as a human, in an amount effective to treat cancer (e.g., reduction in tumor size), e.g., at a dose of about 0.1 GBq to about 30 GBq, suitably administered from a unit dose in a vial or syringe, or as a bulk solution in a vial or syringe prepared from a cold kit prepared with lutetium-177 at a local or central radiopharmaceutical pharmacy or through cGMP central manufacturing.

[0079] In certain embodiments, the subject is suffering from prostate cancer, such as one or more of castration-sensitive prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, advanced stage prostate cancer, drug-resistant prostate cancer such as antiandrogen-resistant prostate cancer (e.g., enzalutamide-resistant prostate cancer, abiraterone-resistant prostate cancer, bicalutamide-resistant prostate cancer), docetaxel-resistant prostate cancer, PARP-resistant prostate cancer, radium chloride-resistant prostate cancer, AR-V7-induced drug-resistant prostate cancer such as AR-V7-induced enzalutamide-resistant prostate cancer, AKR1C3-induced drug-resistant prostate cancer such as AKR1C3-induced enzalutamide-resistant prostate cancer, and combinations thereof.

[0080] In certain embodiments, the subject is a human suffering from metastatic castration-resistant prostate cancer, and is administered an effective amount of 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Lu-PSMA I&T) is administered to a subject to treat prostate cancer.

[0081] In a further particular embodiment, the subject is a human suffering from oligometastatic hormone sensitive prostate cancer and receiving an effective amount of 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Lu-PSMA I&T) is administered to a subject to treat prostate cancer.

[0082] In a further specific embodiment, the subject is a human suffering from metastatic castration-resistant prostate cancer and is administered an effective amount of 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Lu-PSMA I&T) is administered to a subject to treat prostate cancer.

[0083] Administered to patient / animal 177 Lu-PSMA I&T (optically excess structure 2A) 177 An effective amount of a radiopharmaceutical (including Lu-PSMA I&T) is generally determined by consideration of the patient's records. However, an effective amount may suitably be in the range of about 0.1 GBq to about 30 GBq per dose. More particularly, doses may range from about 1 GBq to about 20 GBq or about 30 GBq per dose subject, e.g., 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Lu-PSMA I&T) or about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 6.8, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5 or 30 GBq per dose of This dose may be suitably administered from a unit dose in a vial or syringe, or as a bulk solution in a vial or syringe prepared from a cold kit prepared with lutetium-177 at a local or central radiopharmaceutical pharmacy or through cGMP central manufacturing.

[0084] If necessary or desired, treatment may include administering an effective amount of 177 Lu-PSMA I&T (with optically excess structure 2A) 177The method may include administering two or more doses of a combination of therapies to the subject, including Lu-PSMA I&T. Generally, the combination is administered to the subject 7 to 56 days later, for example at intervals of 4 to 8 weeks. 177 Lu-PSMA I&T (with optically excess structure 2A) 177 Repeated administration of 5-fluorouracil (including Lu-PSMA I&T) is beneficial.

[0085] In a particularly preferred protocol, 177 Lu-PSMA I&T (with optically excess structure 2A) 177 The Lu-PSMA I&T (including) dosage form is a sterile aqueous solution administered by intravenous injection. The dosing regimen may include multiple injections, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 injections, each at an effective dosage, such as 6.8 GBq + / - 10%, administered at intervals of about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 weeks.

[0086] Combination therapy 177 Lu-PSMA I&T (comprising structures 2A and / or 2B above) may be suitably administered to a subject in conjunction or in combination with one or more other therapeutic agents, particularly one or more other chemotherapeutic agents.

[0087] In one embodiment, the subject is receiving rituximab in combination with a regimen of docetaxel and / or prednisone, particularly for subjects with castration-resistant prostate cancer. 177 Treatment with Lu-PSMA I&T (containing structures 2A and / or 2B above) may also be administered.

[0088] In another embodiment, the subject is treated with a regimen that can include chemotherapy such as docetaxel, cisplatin, gemcitabine, cisplatin / gemcitabine, cabazitaxel, one or more antiandrogens, such as one or more LHRH agonists, such as leuprolide and goserelin, or antagonists (e.g., pharmagon and relugolix), one or more antiandrogens, such as flutamide, nilutamide, bicalutamide, cyproterone, abiraterone, enzalutamide, darolutamide, and apalutamide, one or more PARP inhibitors, such as olaparib, rucaparib, or niraparib, particularly for subjects with prostate cancer, including metastatic castration-resistant prostate cancer. 177 Treatment with Lu-PSMA I&T (containing structures 2A and / or 2B above) may also be administered.

[0089] In a further aspect, the subject is treated with a combination of immunotherapy regimes, which may include adoptive cellular therapy or adoptive immunotherapy. 177 Treatment with Lu-PSMA I&T (containing structures 2A and / or 2B above) may also be administered.

[0090] For example, to treat patients suffering from cancer, including to treat diseases associated with cancer or tumor antigen expression; 177 Lu-PSMA I&T (comprising structures 2A and / or 2B above) may be administered in combination with immune effector cells (e.g., T cells, NK cells) engineered to express a chimeric antigen receptor (e.g., CAR T cell therapy).

[0091] For patients / animals with cancer, including prostate cancer: 177 Lu-PSMA I&T (including structures 2A and / or 2B above) may also be administered in combination with other immune-based therapies such as sipuleucel-T (Provenge) or other immune boosting approaches including antibody therapy. For example, in one protocol, to treat patients suffering from cancer, particularly prostate cancer, 177Lu-PSMA I&T (including structures 2A and / or 2B above) may be administered in combination with one or more monoclonal antibodies, such as pembrolizumab (Keytruda), ipilimumab (Yervoy), and / or nivolumab (Opdivo).

[0092] As used herein, the term "in combination" in the context of administering a therapy to a subject refers to the use of two or more therapies for therapeutic benefit.The term "in combination" in the context of administration can also refer to the prophylactic use of a therapy to a subject when used with at least one additional therapy.The use of the term "in combination" does not limit the order in which the therapies (e.g., the first and second therapies) are administered to a subject. The therapy can be administered prior to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior to) administration of the second therapy to a subject in need of the treatment disclosed herein, simultaneously with administration of the second therapy, or after (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) administration of the second therapy. The therapies are administered to the subject in an order and within a time interval such that the therapies can act together. In certain embodiments, the therapies are administered to a subject in a sequence and within a time interval that provides increased benefit than if administered within other sequences and time intervals. Any additional therapy can be administered in any sequence with other additional therapies.

[0093] Packaged 177 Lu-PSMA I&T and Kits Immediately prior to administration in a medical facility, such as a hospital laboratory or a pharmacy that handles radiopharmaceuticals, 177 A cold kit capable of preparing Lu-PSMA I&T (comprising structure 2A and / or 2B above), 177Treatment kits containing Lu-PSMA I&T may be used. In such kits, EuK-Sub-kf-Iodo-y-DOTAGA may be provided in a vial or other container in a lyophilized or other form separated from Lutetium-177. In a medical facility, EuK-Sub-kf-Iodo-y-DOTAGA and Lutetium-177 may be reacted as disclosed herein and then rapidly administered to a patient / animal. 177 Lu-PSMA I&T (containing 2A and / or 2B above) is obtained.

[0094] In a further aspect, 177 Packaged preparations or products of Lu-PSMA I&T (comprising structures 2A and / or 2B above) may also be utilized. Packaged preparations include: 1) 177 Lu-PSMA I&T, and optionally 2) to treat cancers such as prostate cancer 177 The Lu-PSMA I&T may also be provided with instructions for use. Preferably, the packaged preparation contains a therapeutically effective amount of 177 Lu-PSMA I&T (including structures 2A and / or 2B above).

[0095] In certain exemplary packaged preparations or products: 177 The Lu-PSMA I&T (comprising structures 2A and / or 2B above) can be suitably packaged in a suitable container labeled for use as a therapy to treat a subject suffering from, for example, prostate cancer. 177 The product may include Lu-PSMA I&T and preferably one or more ascorbate compounds and one or more gentisate compounds as disclosed herein. 177 The Lu-PSMA I&T may include a container (e.g., a vial, etc.) containing the Lu-PSMA I&T. In addition, the article of manufacture or kit may further include packaging materials, instructions for use, a syringe, a delivery device, for example, to treat a targeted condition, such as prostate cancer or other cancer.

[0096] A packaged system or product may also include instructions (e.g., a printed label or insert or other media (e.g., audio or video files) that explain use of the product). The instructions may be associated with (e.g., affixed to) the container and may describe the manner in which the composition therein is to be administered (e.g., frequency and route of administration), directions therefor, and other uses. The composition may be ready for immediate administration (e.g., dosages are present in suitable units) and may include one or more additional pharma- ceutically acceptable adjuvants, carriers, or other diluents.

[0097] As discussed above, a preferred kit may suitably comprise: a) a pharmaceutical preparation of a lutetium-177 labeled PSMA targeted radioligand agent suitable for intravenous administration to a patient in an amount sufficient to provide a dose of 4-10 Gbq; and b) a package insert containing instructions for use of the radioligand agent in the treatment of a subject exhibiting prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) who has been previously treated with androgen receptor (AR) pathway inhibition but who has not received taxane chemotherapy or for whom taxane chemotherapy is adverse (i.e., is ineligible for or averse to chemotherapy treatment options).

[0098] In certain embodiments, the package insert instructions preferably include guidance for administering the lutetium-177 labeled PSMA targeted radioligand therapy to the patient at least four times, with an inter-dosing interval of four weeks or longer.

[0099] In certain embodiments, the package insert may further include an indication that the shelf life of the lutetium-177 labeled PSMA targeted radioligand is preferably 120 hours from the completion of synthesis and formulation of a pharmaceutical preparation of the lutetium-177 labeled PSMA targeted radioligand for use in the kit.

[0100] In certain embodiments, the package insert preferably further comprises instructions for selecting patients / animals using the PSMA targeted imaging agent.

[0101] In certain embodiments, the package insert preferably further includes instructions to ensure that the patient increases their oral fluid intake and to advise the patient to urinate as frequently as possible to reduce bladder radiation exposure.

[0102] In one particular embodiment, in the kit, the lutetium-177 labeled PSMA targeted radioligand agent is a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

[0103] In one particular embodiment, the kit provides the Lutetium-177 EuK-Sub-kf-Iodo-y-DOTAGA complex in a single dosage form sufficient to provide 6.8 GBq + / - 10% within the effective period.

[0104] In certain embodiments, the package insert further comprises instructions for administering the Lutetium-177 EuK-Sub-kf-Iodo-y-DOTAGA complex to the patient up to four times, with an eight week interval between each administration.

[0105] In one particular embodiment, the pharmaceutical preparation comprises sodium ascorbate in a concentration of 55-75 mg / mL and sodium gentisate in a concentration of 16-36 mg / mL, and has a pH in the range of 5.0-7.0.

[0106] In certain embodiments, the pharmaceutical preparation has a radioactivity concentration (RAC) of 0.5-1.2 GBq / mL, more preferably 0.79-0.86 GBq / mL±10%, at the end of synthesis and formulation of the pharmaceutical preparation.

[0107] In certain embodiments, the pharmaceutical preparation has a total peptide content of 250 μg or less (the sum of EuK-Sub-kf-Iodo-y-DOTAGA and Lutetium-177 EuK-Sub-kf-Iodo-y-DOTAGA complexes), preferably in the range of 180-250 μg.

[0108] In certain aspects, the pharmaceutical preparations are provided in single dose vials and the kits optionally further comprise disposable syringes with syringe shields, e.g., to facilitate handheld injection administration.

[0109] In certain embodiments, the pharmaceutical preparations are provided in disposable syringes having a syringe shield, for example, to facilitate handheld injection administration.

[0110] In certain aspects, the kit may include a radiation-shielded metal pig container (such as a lead or tungsten pig container) in which the pharmaceutical preparation is shipped in the packaged kit.

[0111] In certain embodiments, the package insert meets the following criteria: a) Serum / plasma PSA progression defined as an increase in PSA above nadir >25% and >2 ng / mL; b) Progression on one prior treatment with ARAT in either the CSPC or CRPC setting; c) PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) positive; d) castrate circulating testosterone levels (<1.7 nmol / L or <50 ng / dL), and e) Adequate bone marrow, kidney and liver organ function The method may further include instructions regarding patient / patient eligibility, including that the patient must have progressive mCRPC at the time of consent, based on one or more or all of the following:

[0112] The following non-limiting examples are illustrative.

[0113] Example 1 As described in Example 1 of U.S. Pat. No. 11,129,912, 177 An aqueous composition of Lu-PSMA-I&T is prepared.

[0114] Example 2: Clinical Use The primary efficacy objective was to compare abiraterone or enzalutamide 177 To determine the efficacy of Lu-PSMA I&T and evaluate its efficacy in delaying radiological progression in mCRPC patients with disease progression on androgen receptor axis-targeted therapy (ARAT).

[0115] The primary endpoint of the study may include radiological progression-free survival (rPFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST).

[0116] Further endpoints may include the proportion of patients with partial or complete response (PR or CR, respectively) by BICR based on RECIST 1.1 criteria (soft tissue) and PCWG3 criteria (bone).

[0117] Two treatment arms (arm A and arm B) of human patients will be selected. Arm B treatment will include enzalutamide (160 mg orally once daily) or abiraterone acetate (abiraterone) (1000 mg orally once daily with 5 mg prednisone twice daily or 0.5 mg dexamethasone once daily). Patients randomized to arm B will receive all the benefits of standard clinical care for mCRPC. After progression on control arm treatment, patients will be evaluated and, if eligible, 177 Crossover to Lu-PSMA I&T treatment.

[0118] Study design This study is aimed at patients with mCRPC who have progressed on ARAT treatment. 177 To evaluate the efficacy and safety of Lu-PSMA I&T.

[0119] The study may include three phases: dosimetry, randomized treatment, and long-term follow-up.

[0120] The study will begin with a safety and dosimetry run-in phase of 25 patients and may progress to a randomization phase of approximately 390 patients at the same dose and regimen if pre-specified safety criteria are met. All patients will be followed in long-term follow-up for at least 5 years from first treatment administration until death or loss to follow-up. Patient cohort sizes may vary.

[0121] In one preferred protocol, to assess eligibility, all patients must be screened, such as within 6 weeks prior to enrollment or randomization, must have not received chemotherapy for CRPC, be unfit to receive chemotherapy, or be unwilling to receive chemotherapy, have documented progression on ARAT therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide), and be willing to be treated with second-line ARAT therapy. Once all screening assessments have been performed, patients will be screened for PSMA expression to confirm eligibility. 18 FDCFPyL or 68 Underwent PSMA imaging diagnosis using Ga-PSMA-11 PET / CT.

[0122] For patients who meet the eligibility criteria in the dosimetry phase, a dose of 6.8 GBq (±10%) every 8 weeks for 4 cycles 177 Administer Lu-PSMA I&T. Concurrent with each patient's first treatment cycle, collect whole-body planar acquisitions at five imaging times: 5-2 hours (pre-void), 24 hours (±4 hours), 48 hours (±4 hours), 72 hours (±4 hours), and 140-196 hours. At the 24 or 48 hour time point, SPECT is also recommended but not required.

[0123] Once dosimetry and safety data have been generated to confirm that the selected dose meets pre-specified criteria and the DSMB has given approval to proceed, the randomized treatment phase will begin. The randomized treatment phase will be open to US investigational sites after all patients in the dosimetry phase have completed the treatment follow-up period (i.e., 8 weeks after the last dose). All eligible patients will be randomized in a 2:1 ratio to receive either: ·Group A (n=260): 177 Lu-PSMA I&T 6.8GBq (±10%) every 8 weeks for 4 cycles, or Group B (n=130): enzalutamide (160 mg orally once daily) or abiraterone (1000 mg orally once daily with prednisone 5 mg twice daily or dexamethasone 0.5 mg once daily).

[0124] The primary objective of this study was to compare the efficacy and safety of abiraterone or enzalutamide in delaying radiological progression. 177 The objective of this study was to determine the efficacy of Lu-PSMA I&T. Secondary objectives included: 177 The efficacy and safety of Lu-PSMA I&T are evaluated in 10 patients with ≥ 100% CI, 0.01-0.05 and 0.01-0.05. 177 Objective: To evaluate the efficacy of PSMA-PET for patient selection for Lu-PSMA I&T therapy.

[0125] Patients in the dosimetry phase and in arm A will be evaluated every 2 weeks, and patients in arm B will be evaluated every 4 weeks until completion of the treatment phase (EOT; 32 weeks). In both the dosimetry and randomized treatment phases, patients will be considered to have completed the study if they complete the treatment phase at study week 32 (EOT visit). If patients have not progressed to EOT, disease assessment based on CT / MRI and whole body bone scan will continue every 8 weeks until radiological progression by BICR.

[0126] Patients randomized to Arm B who had experienced radiological progression by BICR, had not initiated an interventional procedure, and had no uncontrolled AEs received 6.8 GBq (±10%) every 8 weeks for 4 cycles. 177 Patients are eligible to cross over to receive Lu-PSMA I&T. Crossed-over patients will be followed for safety and efficacy based on SOA, with the exception of ECG, corrlelative blood draws, and imaging interpretations assessed by BICR.

[0127] A subset of up to 20 patients in Group A from selected centers will have PK evaluation using blood and urine samples.

[0128] Efficacy will be assessed by CT / MRI scans of the chest, abdomen, and pelvis, total body bone scan, PSA measurement, Eastern Cooperative Oncology Group (ECOG) Health-Related Quality of Life (HRQoL) questionnaire, pain questionnaire, and skeletal events review.

[0129] Safety will be assessed by measurements of body weight, physical examination, vital signs, ECG, blood chemistry and hematology parameters, assessment of AEs / serious AEs (SAEs), and assessment of concomitant medications.

[0130] Patients in the control group (Group B) will be evaluated based on the same procedures as the investigational group (Group A), with the exception of ECG performed after baseline and PK samples taken only in Group A, and treatment compliance confirmed at each visit for Group B.

[0131] An independent Data Safety Monitoring Committee (iDSMB) will monitor ongoing safety data (AEs and laboratory results).

[0132] The long-term follow-up phase will consist of scheduled visits or phone calls every 3 months to assess vital status, late radiation-related toxicity, and new anticancer therapies for at least 5 years from first treatment administration until death or loss to follow-up.

[0133] Study population 25 patients will be enrolled in the dosimetry phase of the study. A total of 390 patients will be randomized in a 2:1 ratio in the treatment phase: 260 patients will be randomized to 177 130 patients will receive Lu-PSMA I&T and abiraterone or enzalutamide.

[0134] Prospective approval of protocol deviations from recruitment and enrollment criteria, also known as protocol waivers or exemptions, will not be permitted.

[0135] Inclusion criteria Patients are eligible for inclusion in the study only if all of the following criteria apply: 1.Males aged 18 or older. 2. Histologic, pathologic, and / or cytologic confirmation of adenocarcinoma of the prostate. 3. Ineligible for or refuses chemotherapy treatment options. 4. Patients must have progressive mCRPC at the time of consent based on at least one of the following criteria: Serum / plasma PSA progression defined as an increase in PSA above nadir by more than 25% and more than 2 ng / mL, confirmed by progression at two time points at least 3 weeks apart. b. Soft tissue progression defined as a 20% or greater increase in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment began, or the appearance of one or more new lesions. c. Progression of bone disease: Evaluable disease by bone scan or one new bone lesion 5. Progression on prior treatment with one ARAT (abiraterone or enzalutamide or darolutamide or apalutamide) in either the CSPC or CRPC setting. 6. Positive PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) as determined by the sponsor's central reader. 7. Castrate circulating testosterone levels (<1.7 nmol / L or <50 ng / dL). 8. Adequate organ function, not transfusion dependent: a. Bone marrow reserve: i. White blood cell (WBC) count ≥ 2.5 x 109 / L or absolute neutrophil count (ANC) ≥ 1.5 x 109 / L. ii. Platelets ≥100×109 / L. iii. Hemoglobin ≥ 8 g / dL. b. Liver function: Total bilirubin ≦1.5× institutional upper limit of normal (ULN). For patients with known Gilbert syndrome, ≦3×ULN is acceptable. ii. ALT and AST ≤ 3.0 x ULN. c. Renal function: i. Serum / plasma creatinine ≦1.5×ULN or creatinine clearance ≧50 mL / min based on the Cockcroft-Gault equation. D. Albumin ≥ 30 g / L. 9. Patients infected with human immunodeficiency virus who are healthy and at low risk for acquired immune deficiency syndrome-related outcomes will be enrolled in this study. 10. For patients with partners of childbearing potential, the partner and / or patient must use an appropriate barrier method of contraception deemed acceptable by the principal investigator during the study and for 6 months after the last study drug dose. 11. Willingness to initiate investigator-specified ARAT therapy (either enzalutamide or abiraterone) if randomized to Arm B. 12.ECOG performance status 0-1. 13. All study requirements and treatments ( 177 Willing and able to comply with the requirements of the IRS (including Lu-PSMA I&T) and the timing and nature of any evaluations that may be required. 14. Signed informed consent.

[0136] Exclusion criteria Patients will be excluded from the study if any of the following criteria apply: 1. Prostate cancer with known significant (present in >10% of cells) sarcomatoid or spindle cell or neuroendocrine components, if noted in the pathology report. Any small cell component in the cancer should result in exclusion. 2. Any prior treatment for prostate cancer within 28 days prior to randomization, except for first-line focal external beam, ARAT, luteinizing hormone releasing hormone (LHRH) agonist or antagonist therapy, or non-radioactive bone-targeted agents. 3. Any prior cytotoxic chemotherapy for CRPC (e.g., cabazitaxel or docetaxel); chemotherapy for hormone-sensitive prostate cancer (HSPC) is permitted if the last dose was administered >1 year prior to consent. 4. Previous treatment with systemic radionuclides (e.g., radium-223, rhenium-186, strontium-89). 5. Previous immunotherapy, excluding sipuleucel-T. 6. Prior PSMA-targeted radioligand therapy. 7. Conventional poly ADP-ribose polymerase (PARP) inhibitors for prostate cancer. 8.Patients who have progressed on 2 or more lines of ARAT. 9. Patients receiving bone-targeted therapy (e.g., denosumab, zoledronic acid) must have been taking it continuously for at least 4 weeks prior to randomization. 10.Receipt of investigational drug for 60 days or 5 half-lives (whichever is shorter) or less prior to randomization. 11. Major surgery within 30 days prior to randomization. 12. Estimated life expectancy less than 6 months as assessed by the principal investigator. 13. Presence of liver metastases larger than 1 cm on abdominal imaging. 14. Superscan on bone scan, defined as a bone scan showing significantly increased skeletal radioisotope uptake compared with soft tissues, accompanied by absent or weak urogenital tract activity. 15. Use of opioids for cancer-related pain within 30 days prior to consent. 16. Known presence of central nervous system metastases. 17. Contraindications to the planned use of ARAT therapy. 18. Active malignancies other than low-grade non-muscle-invasive bladder cancer and non-melanoma skin cancer. 19. Concomitant illness that may compromise the patient's ability to undergo study procedures. 20. Significant psychological, familial, sociological or geographic conditions that may interfere with compliance with the study protocol and follow-up schedule. Patients who travel should be able to make repeat visits, even if they are in the control group. 21. Symptomatic spinal cord compression or clinical or radiological evidence of impending spinal cord compression. 22. Any concurrent serious (as determined by the Investigator) medical condition, including but not limited to, New York Heart Association class III or IV congestive heart failure, unstable ischemia, uncontrolled symptomatic arrhythmias, history of congenital long QT syndrome, uncontrolled infection, known active Hepatitis B or C, or other significant comorbid condition that in the Investigator's opinion would impair study participation or cooperation.

[0137] screening Patients will be screened within 6 weeks prior to randomization.

[0138] Study intervention The objective of the dosimetry phase is to evaluate dosimetry in all standard organs, including the kidneys, salivary glands, and lacrimal glands. Individual dosimetry estimates and summary statistics will be generated by a central dosimetry core laboratory.

[0139] Prior to entering the dosimetry phase, patients will sign an ICF and undergo screening procedures including a PSMA-PET scan. A total of 25 patients who meet all eligibility requirements will receive 6.8 GBq (±10%) of 177Lu-PSMA I&T every 8 weeks for 4 cycles.

[0140] A baseline CT scan is acquired for the purpose of determining kidney volume for patient-specific correction in the dosimetry analysis process.

[0141] Concurrent with each patient's first treatment cycle, five whole-body conjugate view planar images will be acquired at the times listed below on a whole-body scanning capable dual-head gamma camera with a medium energy collimator. Images should include the entire body from head to toes, and all parts of the body, including the arms, should be completely included within the field of view. An imaging standard with a known amount of radioactivity should be present in each image acquired. Record the date and time of each image acquisition, as well as the scan rate for each image. Although not required, facilities are also encouraged to acquire quantitative or semi-quantitative SPECT images at any time during the following 24 or 48 hours for supplemental dosimetry analysis. If only a single optional SPECT image is acquired, 48 hours is the preferred acquisition time, followed by 24 hours. Further details of whole body planar acquisitions and SPECT acquisitions are included in the Imaging Diagnostic Manual.

[0142] Whole body image acquisition time: 0.5 to 2 hours (before urination) 24 hours (± 4 hours) 48 hours (± 4 hours) 72 hours (± 4 hours) ·140~196 hours

[0143] The central dosimetry core laboratory performs image quantification, kinetic modeling, and dosimetric analysis across all standard organs utilizing standard MIRD / RADAR methodologies.

[0144] Regions of interest (ROIs) are constructed on the images for all organs / tissues showing uptake and radioactivity in the ROIs is quantified at each time point. Red bone marrow radioactivity is estimated using bone marrow ROI or blood-based methodologies. Kinetics are modeled to obtain normalized decay numbers and dosimetry estimates are generated for all organs / tissues based on the generated activity-time curves and derived residence times utilizing OLINDA / EXM v2 software. CT-derived organ masses are used to more accurately estimate kidney absorbed dose.

[0145] After each of four treatment cycles, patients will be evaluated every 2 weeks until Week 32 (8 weeks after the last cycle) to monitor tolerability and safety (i.e., severity, frequency and duration of AEs / SAEs, vital signs, ECG, hematology and chemistry). Safety assessments of all AEs including xerostomia, dry eye, and renal function, as well as laboratory abnormalities will be followed closely for worsening or resolution of severity and to evaluate whether dose modifications for subsequent cycles may be warranted.

[0146] An iDSMB will convene to evaluate safety outcomes after the first five patients have completed treatment, or sooner if requested by the medical monitor. The iDSMB will evaluate safety until all 25 patients have been enrolled and completed treatment.

[0147] Efficacy will also be assessed based on radiological tumor assessments, PSA blood samples, ECOG and QoL.Radiological responses will be collected and evaluated by BICR throughout the dosimetry phase.

[0148] Prespecified criteria for dose selection in the randomization phase To ensure that doses are kept the same during the randomized treatment phase, the following criteria are used: Dosimetry and safety Dosimetry data from the run-in period showed a mean absorbed kidney dose of less than 20 Gray (Gy). Based on ongoing data evaluation and stopping rules, no clinical toxicity concerns were identified during the dosimetry and safety run-in phase by the independent Data Safety Monitoring Board (iDSMB), medical monitors, investigators, or FDA. · The investigator does not want to increase the dose or shorten the interval between doses because of the preliminary efficacy observed based on PSA response.

[0149] The following criteria will be used to determine dose modifications in the randomized treatment: If the mean absorbed renal dose obtained from the dosimetry and safety run-in phase exceeds 20 Gy, the fourth dose for each patient's treatment regimen in the randomized treatment phase will be reduced to a level calculated from the linear dosimetry data curve to ensure that the mean absorbed renal dose is 20 Gy or less. If more than 45% of patients in the dosimetry and safety run-in phase experience a dose reduction to 5GBq after their first treatment dose, based on the dose modification criteria described below, a reduced dose of 5GBq will be implemented for all cycles in the randomized treatment phase. If preliminary efficacy is not observed based on descriptive assessment of PSA reduction, the investigator will stop the study and meet with FDA before implementing the dose escalation paradigm.

[0150] Randomized Treatment Phase Once dosimetry and safety data have been generated to confirm that the selected dose meets pre-specified criteria and the DSMB has given approval to proceed, the randomized treatment phase will begin. The randomized treatment phase will be open to investigational sites after all patients in the dosimetry phase have completed the entire follow-up period (i.e., 8 weeks after the last dose), or earlier if FDA consent is obtained. Patients will sign an ICF and undergo screening procedures including a PSMA-PET scan. Following eligibility determination, patients will be randomly assigned 2:1 to the following groups: Group A, approximately 260 patients 177 They will undergo Lu-PSMA I&T (6.8GBq (±10%) every 8 weeks for 4 cycles). · Arm B, approximately 130 patients will receive enzalutamide (160 mg orally once daily) or abiraterone (1000 mg orally once daily plus prednisone 5 mg twice daily or dexamethasone 0.5 mg once daily).

[0151] Randomization will be stratified by prior taxane treatment for castration-sensitive prostate cancer (CSPC) (yes or no), prior bisphosphonate use (yes or no), prior ARAT metastatic status (M0 or M1), and measurable disease at study entry (yes or no).

[0152] Patients in both treatment arms are strongly encouraged to continue their randomized treatment until objective radiological disease progression as assessed by BICR. All patients will undergo disease assessment with total body bone scan and CT / MRI imaging of the chest, abdomen, and pelvis. Patients will also be assessed for changes in Eastern Cooperative Oncology Group (ECOG), central laboratory PSA measurements, HRQoL questionnaires, pain questionnaires, and skeletal event adjudication. Safety will be assessed by weight measurement, physical examination, vital signs, electrocardiogram (ECG), blood chemistry and hematology parameters, adjudication of AEs / SAEs, and adjudication of concomitant medications.

[0153] ARAT dosing in the control group will be modified according to approved product labeling. 177Lu-PSMA I&T doses may be modified according to the guidelines set forth below.

[0154] Patients will be assessed in clinic every 2 weeks (± 2 days) in Arm A and every 4 weeks (± 2 days) in Arm B until completion of the treatment phase (EOT; 8 weeks after the last dose), as appropriate. If there is no BICR-assessed radiological progression by EOT, patients will continue to receive follow-up every 8 weeks until BICR-assessed radiological progression, following all procedures outlined within the SOA for these visits. Every effort should be made to keep patients on their assigned treatment until BICR-assessed radiological progression. If the investigator chooses to initiate an alternative anticancer therapy prior to BICR-assessed radiological progression. Patients will continue to receive follow-up every 8 weeks until BICR-assessed radiological progression, regardless of discontinuation of study intervention or initiation of subsequent anticancer therapy. Once patients have BICR-assessed radiological progression, they will complete a Progression Visit and If EOT / safety follow-up has already occurred (and patients have not crossed over if randomized to Arm B), they will enter the Long-Term Follow-up (LTFU) phase for at least 5 years from first treatment administration until death or loss to follow-up. If an EOT / safety follow-up visit was not performed (and the patient did not cross over if randomized to Arm B), they will remain on their study schedule until 8 weeks after their last dose, complete the EOT / safety follow-up visit, and then enter LTFU. Crossover patients in Arm B will proceed to Cycle 1, Week 0 and follow the Arm A SOA (excluding ECG and correlative samples).

[0155] If the primary rPFS analysis occurs before a patient progresses by BICR, the patient will continue on the original study schedule until investigator-assessed radiological progression, death, or loss to follow-up.

[0156] The iDSMB will monitor ongoing safety data (AEs / SAEs, ECGs, laboratory results) every 3 months throughout the treatment phase. A subset of up to 20 patients in Arm A will also be evaluated for PK.

[0157] Patients in arm B who have experienced radiological progression by BICR, have not initiated an interventional procedure, and have no uncontrolled AEs will receive 6.8 GBq (± 10%) every 8 weeks for 4 cycles. 177 Patients are eligible for consent to crossover to receive Lu-PSMA I&T. Radiologic assessment of second progression will be performed by the investigator and patients will be monitored for safety based on the schedule shown below.

[0158] Long-term follow-up phase The long-term follow-up phase for the dosimetry and randomized treatment phase will consist of scheduled visits or calls every 3 months to assess vital status, late radiation-related toxicity, second progression, and new anticancer therapy for at least 5 years until death or loss to follow-up. The entire study will end when the last subject completes the last study-related call or visit, discontinues the study, or is lost to follow-up.

[0159] 68 Ga-PSMA-11 and 18 F-DCFPyL 68 The Ga-PSMA-11 radiopharmaceutical will be administered intravenously at a dose of 5 mCi + / - 10%. 18 The F-DCFPyL radiopharmaceutical will be administered intravenously at a dose of 9 mCi + / - 10%.

[0160] 177 Storage and handling of Lu-PSMA I&T To limit exposure: 177Lu-PSMA I&T will be stored in a lead-shielded container. 177Lu-PSMA I&T will be shipped in International Air Transportation Association (IATA) approved packaging and marked with the appropriate radioactive label. Once received, it should be stored in a cool, dark place until needed for injection. 177 The Lu-PSMA I&T may remain in the shipping container. Shipping documents should include the ART.

[0161] The drug is stored at room temperature (15-30°C) in lead pots at the clinical site. If stored in its original packaging, the shelf life is 2 days after the radioactive reference time, after which the drug product should be properly disposed of.

[0162] 177 Preparation and Administration of Lu-PSMA I&T 177 Administration of Lu-PSMA I&T should occur by the labeled expiration date. The time of all measurements should be documented relative to a single clock. If possible, the dose calibrator clock should be synchronized to this reference clock. The amount of radioactivity in the vial should be measured before and after each administration. Once dose measurements and times are entered into the eCRF, the decay-corrected administered dose is calculated in the eCRF.

[0163] 177 Prior to Lu-PSMA I&T administration, an indwelling IV catheter should be inserted into the antecubital vein (preferably). The IV line should be flushed with at least 10 mL of saline to ensure patency. The dose should be administered by slow pushing or using an automated pump over 1-10 minutes under close observation to prevent dose extravasation. Once administration is complete, the line should be flushed with at least 10 mL of saline.

[0164] If necessary, the infusion may be interrupted to accommodate the patient (e.g., patient needs to use the toilet, experiences nausea or vomiting, anxiety). The infusion should be continued unless the investigator determines that administration presents an unacceptable risk, an undue safety hazard, or the patient's medical condition deteriorates so rapidly that the infusion cannot be continued or interferes with medical or surgical care. If it is possible to complete the infusion on the scheduled day, the infusion should proceed, even with interruptions.

[0165] Control group Patients randomized to Arm B will receive abiraterone or enzalutamide as defined below. Patients progressing on either enzalutamide, darolutamide or apalutamide will receive prednisone at a dose of 5 mg twice daily in addition to abiraterone 1000 mg once daily per approved product labeling. Patients progressing on abiraterone will receive either 1) enzalutamide 160 mg once daily prescribed in accordance with the approved product labeling, or 2) abiraterone 1000 mg once daily prescribed in accordance with the approved product labeling plus dexamethasone at a dose of 0.5 mg once daily.

[0166] Except for dose modifications according to product labeling, patient treatment must remain unchanged throughout the randomized treatment phase.

[0167] Treatment Compliance 177 Lu-PSMA I&T, 18 F-DCFPyL, and 68 Ga-PSMA-11 will be administered under the supervision of the Investigator or qualified designee. Details of the study drug injection will be recorded in each patient's eCRF.

[0168] Abiraterone or enzalutamide treatment regimens will be self-administered according to standard clinical dosing. Patients will be instructed to administer treatment according to standard of care and appropriate agency-approved drug labeling. Adherence to the prescribed dosing schedule will be assessed at each visit and information will be entered into the eCRF.

[0169] Randomization, stratification, and blinding Randomization will be performed in a 2:1 ratio using the IVRS / IWRS after confirming patient eligibility and before starting study treatment. The enrollment process will involve the following steps: · The investigator will obtain written informed consent from the patient before any study-specific procedures are performed. Screening records of patients who consent to the study should be kept by the investigator at the site. All patients who sign the consent will be assigned a unique sequential registration number using the Interactive Voice / Web Response System (IVRS / IWRS). This registration number will be used to identify the patient on study documentation and eCRFs. Randomization will be performed using the IVRS / IWRS upon determination of patient eligibility, including confirmation of PSMA uptake by BICR. Patients will begin receiving study treatment ( 177 Patients should begin 177Lu-PSMA I&T (either 177Lu-PSMA I&T or control group). The maximum time between randomization and the first dose of treatment for the control group is 3 weeks. The timing of 177Lu-PSMA I&T for patients will be determined by drug delivery and stability timelines.

[0170] Patient stratification Randomization will be stratified by prior taxane treatment for castration-sensitive prostate cancer (CSPC) (yes or no), prior bisphosphonate use (yes or no), prior ARAT metastatic status (M0 or M1), and measurable disease at study entry (yes or no).

[0171] Previous and Concurrent Treatments All treatments (medications, including over-the-counter or prescription drugs, vitamins, and / or herbal supplements, or medical procedures) completed by the patient within 30 days prior to randomization must be recorded in the eCRF, including the reason for use, dates of administration including start and end dates, and dosing information including dose and frequency.

[0172] Permitted / prohibited drugs Permitted Drugs The following medications are permitted in either group: Patients who had not previously been surgically castrated must have been receiving and be willing to continue receiving LHRH analog treatment throughout the study. Pre-specified continued use of glucocorticoids to prevent secondary mineralocorticoid excess syndrome is permitted but should not be added after randomization unless prescribed as part of the ARAT regimen for Arm B. Pre-specified bisphosphonates or denosumab are permitted, provided they are stable in dose and initiated at least 4 weeks prior to study treatment, but should not be initiated after randomization. Palliative external beam radiation. Palliative surgical procedures to treat skeletal-related events. Opioids for cancer-related pain are not permitted within 30 days prior to consent, but may be initiated after randomization.

[0173] Investigator discretion should be used for any deviations from the above guidelines to ensure patient safety. Deviations should be recorded in the eCRF and communicated to the Investigator for evaluation of continuing eligibility.

[0174] Prohibited Drugs In certain embodiments, the following medications are prohibited during participation in the study: Other investigational drugs. Other systemic radioisotopes. ·Poly ADP-ribose polymerase inhibitors. ·Cytotoxic chemotherapy. Hemibody radiation therapy.

[0175] Dose change Control group Androgen receptor inhibitor (ARAT) dosing in the control group will be modified according to approved product labeling.

[0176] 177 Lu-PSMA I&T Dose Reduction If a patient experiences any of the following toxicities, further dosing at 6.8 GBq should be discontinued and subsequent doses should be reduced to 5 GBq once the subject meets the criteria for resuming treatment. Grade 3 or greater hematological toxicity, including severe neutropenia defined as ANC <1.0 x 109 / L; thrombocytopenia defined as a platelet count between 50.0 x 109 / L and less than 25.0 x 109 / L accompanied by Grade 2 or greater bleeding; or Grade 4 thrombocytopenia (platelet count <25 x 109 / L) lasting for 1 week with or without bleeding or with a platelet count less than 10,000 / μL at any time. Grade 3 or greater treatment-related nephrotoxicity defined as 1) creatinine elevation >3.0 × ULN or 2) renal disease defined as CrCl <15 mL / min / 1.73 m2. CTCAE v5.0 Grade 1 or Grade ≥ 3 xerostomia, sialadenitis, or dry eye that did not decrease to baseline levels by the next treatment cycle. Any other significant treatment-related toxicity deemed dose-limiting by the investigator.

[0177] If dosing is interrupted, subjects should be evaluated biweekly with CBC and / or blood chemistry including creatinine and AE monitoring until dose-limiting toxicities are CTCAE v5.0 grade 1 or less or have returned to baseline values ​​before dosing can be resumed at 5 GBq. If values ​​have not returned by 16 weeks after the previous dose, permanent discontinuation from further dosing should occur and subjects will be asked to remain on the study to follow disease progression, safety, and survival.

[0178] 177 Delayed Lu-PSMA I&T administration In addition to the criteria identified above: 177 Lu-PSMA I&T administration may also be delayed for any other reason at the investigator's discretion and in consultation with the medical monitor.

[0179] If administration is delayed for more than 16 weeks, permanent discontinuation should occur.

[0180] Discontinuation of study intervention Patients may discontinue study treatment for the following reasons: -Patient's free decision. AE / SAE. Significant non-compliance with study protocol procedures and evaluations as determined by the investigator and / or principal investigator. Objective radiological progression by BICR as defined by RECIST 1.1 and PCWG3. Unequivocal Clinical Progression: 1) Initiation of chronic opioid use for new onset of prostate cancer pain suspected to be due to disease progression. Chronic use is defined as more than 7 consecutive days or more than 10 daily days within a 14-day period, or 2) imminent need to initiate cytotoxic chemotherapy, or 3) radiation therapy or surgical therapy for a complication of prostate cancer progression, excluding palliative radiation therapy (in the treatment of pain at the site of bone metastases present at baseline, unless indicating disease progression), or 4) deterioration of ECOG performance status to ≥ 3 due to prostate cancer. If dosing is delayed for more than 16 weeks, a permanent discontinuation should be made. The reason for discontinuing study treatment must be recorded in the eCRF with all relevant details (date of discontinuation, associated symptoms, and applicable treatment). Any interruption of study treatment must be communicated to the Investigator within 48 hours of the site investigator becoming aware of the event.

[0181] If patients discontinue study treatment prior to being declared radiological progression as assessed by BICR, they should be followed for radiological progression by BICR and OS according to the schedule of evaluations.

[0182] Late radiation toxicities (eg, secondary malignancies and nephrotoxicity) will be collected throughout LTFU.

[0183] Withdrawal of patients from the study A patient will be considered to have withdrawn from the study if he or she discontinues study treatment and protocol-mandated evaluations. Patients may be removed from the study for the following reasons: Inaccurate enrolment (i.e. enrolment despite not meeting the eligibility criteria). ·Patient discretion (i.e. voluntary withdrawal). Lost to follow-up. ·death.

[0184] For all patients who withdraw consent, the reason should be recorded in the eCRF. If a patient withdraws consent for future disclosures of information, the investigator may retain and continue to use any data collected prior to such withdrawal of consent.

[0185] If a patient withdraws from the study, the patient may request the destruction of any samples that were collected but not tested, and the Investigator must document this in the site's study records.

[0186] Early termination of the trial Stopping rules apply to both the dosimetry phase and the randomized treatment phase. A study may be interrupted, or possibly halted, for any of the following reasons: The cause of death was unexpected and at least 177 Any patient death assessed as possibly related to Lu-PSMA I&T and deemed, in the opinion of the Investigator, to contraindicate further dosing of the study patient. Any treatment-related event that, in the judgment of the Medical Monitor, is deemed serious enough to require immediate adjudication by the iDSMB. This may include any treatment-related symptomatic and / or irreversible treatment-related grade 4 hematologic toxicity, nephrotoxicity, lacrimal gland toxicity (e.g., dry eye), or salivary gland toxicity (e.g., xerostomia). - In the opinion of the DSMB and the investigator, further medication of the study patient is contraindicated 177 Any other safety findings evaluated in relation to Lu-PSMA I&T.

[0187] Screening Procedure The following procedures and assessments will be performed after the patient has provided written informed consent and prior to randomization into the study. Procedures performed as part of the patient's routine clinical management (e.g., blood counts) and obtained prior to signing of the ICF may be utilized for screening or baseline purposes if the procedure meets the criteria specified in the protocol and is performed within the timeframe established in the SOA.

[0188] All screening procedures required to confirm study eligibility must be completed within 6 weeks prior to enrollment or randomization. All data will be recorded on the eCRF.

[0189] Timing of the survey Clinical evaluation: medical history, complete physical examination, morphometric measurements (height, weight), vital signs, ECG, ECOG, records of SAEs, records of previous medications, records of concomitant medications within 6 weeks prior to enrollment / randomization (for all subjects).

[0190] Treatment History Pathology and / or Histology Tumor Markers PSA Hematology WBC count, 3-part differential, RBC count, hemoglobin, hematocrit, mean corpuscular volume, platelet count Blood Chemistry Previous treatment for prostate cancer including electrolytes (sodium, potassium, calcium, chloride, bicarbonate, phosphate, magnesium), total protein, serum creatinine, albumin, glucose (non-fasting), ALP, LDH, CK, total bilirubin, AST, ALT.

[0191] Additional blood tests testosterone Radiology PSMA-PET Optional 18 F-FDG PET After all other eligibility requirements have been completed, and within 30 days prior to randomization. Diagnostic imaging CT / MRI chest, abdomen, pelvis using RECIST v1.1 criteria as outlined in PCWG3 recommendations; Total body bone scan, up to 6 weeks prior to enrollment / randomization.

[0192] Timing of the survey 177 Clinical evaluation before Lu-PSMA I&T administration Limited physical exam, weight measurement, ECOG each 177 Before Lu-PSMA I&T infusion and at the last visit of each cycle during treatment (weeks 4, 8, 12, 16, 20, 24 and 28), and at EOT 177 Clinical evaluation before and after Lu-PSMA I&T administration. ECG 177 Pre- and post-infusion (within 4 hours of administration) and EOT of all Lu-PSMA I&T treatments Tumor marker PSA first 177 Week of Lu-PSMA I&T treatment, pre-infusion, and every 4 weeks during treatment, at progression visits, at EOT, and every 8 weeks until progression if progression has not occurred by EOT Hematology WBC count, WBC particle size distribution (trimodal), RBC count, hemoglobin, hematocrit, mean corpuscular volume, platelet count 177 Before Lu-PSMA I&T infusion, every 2 weeks during infusion, at progression visits, and at EOT Blood chemistry: electrolytes (sodium, potassium, calcium, chloride, bicarbonate, phosphate, magnesium), total protein, serum creatinine, albumin, glucose (non-fasting), ALP, LDH, CK, total bilirubin, AST, ALT Vital signs: blood pressure, heart rate, temperature, respiratory rate Dosimetry Whole-body planar images at baseline (0.5–2 h [prevoid], 24 h [±4 h], 48 h [±4 h], 72 h [±4 h], and 140–196 h). Diagnostic Imaging CT / MRI Chest, Abdominal, Pelvic, Whole Body Bone Scan Weeks 8, 16, 24, EOT, and every 8 weeks until progression From first administration of investigational drug (i.e., PSMA imaging agent) to EOT per visit SAE Screening to EOT per visit Late radiation toxicity If no progression has occurred by EOT, every 8 weeks until LTFU

[0193] Concomitant medications Concomitant medications: Every visit until EOT If progression has not occurred by EOT, use of anticancer therapy (although prohibited) will be collected every 8 weeks until progression. Opioid use Opioid medication determination Visit-by-visit until initiation of opioid use Quality of Life FACT-P Baseline and Weeks 8, 16, 24, and EOT Pain assessment BPI-SF, AQA, bone event assessment Day 1 and the last visit and EOT of each cycle (Weeks 4, 8, 12, 16, 20, 24 and 28) during the treatment period If progression has not occurred by EOT, complete AQA every 8 weeks until progression. Imaging PSMA PET progression time point

[0194] 177 Lu-PSMA I&T randomization treatment period Patients randomly assigned to group A were 177 The following investigations will be performed during the Lu-PSMA I&T treatment cycle:

[0195] Timing of the survey 177 Clinical evaluation before Lu-PSMA I&T administration Limited physical exam, weight measurement, ECOG 177 Visits at the end of each cycle (weeks 4, 8, 12, 16, 20, 24, and 28) before and during Lu-PSMA I&T infusion, and EOT Clinical evaluation before and after administration of 177LuPNT2002 ECG 177 Pre- and post-infusion (within 4 hours after administration) of all Lu-PSMA I&T treatments and at EOT, tumor marker PSA first 177 Week of Lu-PSMA I&T treatment, pre-infusion, and every 4 weeks during treatment, at progression visits, at EOT, and every 8 weeks until progression if no progression had occurred by EOT Hematology WBC count, WBC size distribution (trimodal), RBC count, hemoglobin, hematocrit, mean corpuscular volume, platelet count 177 Before and every 2 weeks during Lu-PSMA I&T infusions, at progression visits, and at EOT Blood chemistry: electrolytes (sodium, potassium, calcium, chloride, bicarbonate, phosphate, magnesium), total protein, serum creatinine, albumin, glucose (non-fasting), ALP, LDH, CK, total bilirubin, AST, ALT Vital signs: blood pressure, heart rate, temperature, respiratory rate

[0196] Correlation Samples (Optional) Circulating factors to predict response Baseline and Weeks 8, 16, 24, and EOT PK blood and urine samples (up to 20 patients from selected centers) Baseline Imaging CT / MRI chest, abdomen, pelvis, whole body bone scan at weeks 8, 16, 24, EOT, and every 8 weeks until progression Toxic AE 177 All visits from first dose of Lu-PSMA I&T through EOT All visits from SAE screening to EOT Late radiation toxicity If no progression has occurred by EOT, every 8 weeks until completion of LTFU

[0197] Concomitant medications Concomitant medications assessed: every visit until EOT. If progression has not occurred by EOT, use of anticancer therapies (although prohibited) will be collected every 8 weeks until progression.

[0198] Timing of the survey Opioid use Opioid medication determination Visit-by-visit until initiation of opioid use Quality of Life FACT-P Baseline and Weeks 8, 16, 24, and EOT Pain assessment BPI-SF, AQA, bone event assessment Day 1 and Weeks 4, 8, 12, 16, 20, 24 and 28 during the treatment period and at EOT If progression has not occurred by EOT, AQAs will be completed every 8 weeks until progression. 177 Lu-PSMA I&T infusions will be administered on the first day of each cycle and will end on the fourth cycle (maximum number of cycles). The first cycle will begin at the first visit (week 0) and will occur every 8 weeks thereafter.

[0199] Control treatment Patients randomized to Arm B will be treated with abiraterone or enzalutamide and undergo the following investigations: Patients in Arm B who progress will be evaluated and, if eligible, 177 Crossover to give Lu-PSMA I&T.

[0200] Control treatment Timing of the survey Clinical evaluation: limited physical exam, weight, vital signs, ECOG status Before the first control treatment and then every 4 weeks until EOT. Tumor marker PSA baseline (before first control treatment) and every 4 weeks during treatment, at progression visits, at EOT, and every 8 weeks until progression if no progression had occurred by EOT Hematology WBC count, white blood cell trimodal size distribution, RBC count, hemoglobin, hematocrit, mean corpuscular volume, platelet count at baseline (before receiving first control treatment), every 4 weeks, at progression visits and at EOT Blood Chemistry Electrolytes, Serum Creatinine, Glucose (non-fasting), Calcium, Phosphate, Magnesium, Albumin, Total Protein, ALP, LDH, CK, Bilirubin, ALT, AST Vital signs: blood pressure, heart rate, body temperature, respiratory rate Diagnostic Imaging CT / MRI Chest, Abdominal, Pelvic, Whole Body Bone Scan Weeks 8, 16, 24, EOT, and every 8 weeks until progression Toxicity AEs: All visits from the first administration of clinical trial drug product (i.e., PSMA imaging agent) through EOT (AE assessments should be every 2 weeks and can be conducted via phone call unless other procedures are required. All visits from SAE screening through EOT (SAE assessments should be every 2 weeks and can be done via phone call if no other procedures are required) Concomitant Medications Determination of Concomitant Medications All visits leading up to the EOT If progression has not occurred by the EOT, use of anticancer therapy (although prohibited) will be collected every 8 weeks until progression. Opioid use Opioid medication determination Visit-by-visit until opioid initiation Quality of Life FACT-P: Day 1, Weeks 8, 16, 24 and EOT during treatment Pain assessment BPI-SF, AQA, bone event assessment Day 1 and Weeks 4, 8, 12, 16, 20, 24 and 28 during the treatment period and at EOT If progression has not occurred by EOT, collect AQA every 8 weeks until progression. Compliance with Treatment: Assessment of compliance with treatment from baseline to EOT

[0201] Progress visits and crossovers All patients who demonstrate progression (as above) will undergo the following procedures and all data will be recorded in the eCRF. ·Assessing and recording vital signs. PSA test. ·AE / SAE evaluation and recording. · Assess and document concomitant medications, including opioid use. Final assessment and recording of compliance with control treatment (Group B). ·Hematology. ·Blood chemistry. Time to second progression as assessed by investigator.

[0202] For patients in group A, subsequent follow-up for patients who met individual criteria for progression (radiological, biochemical, or clinical) was 177 Continued administration of Lu-PSMA I&T infusions will be determined in discussion between the investigator and study leader.

[0203] For patients in Arm B who are eligible for crossover as defined below, at week 0 of cycle 1 in the SOA 177 Lu-PSMA I&T will be initiated. However, for these patients, ECG and correlative samples are not required and imaging will be considered on-site. If the patient does not elect to cross over and has not completed the EOT visit, they should remain on their study schedule until 8 weeks after their last dose, complete the EOT / safety follow-up visit, and then enter LTFU.

[0204] To determine eligibility for crossover, patients in Arm B must undergo the following assessments. These can be done as part of their progression visit. If it has been more than 30 days since their progression visit, these should be repeated. Final assessment and recording of compliance with control treatment (Group B). -Vital signs. Hematology, blood chemistry, and PSA. AEs / SAEs, concomitant medications including opioid use, and skeletal events adjudication. ·FACT-P and BPI-SF questionnaires. ·AQA. · Tumor evaluation (CT / MRI and whole body bone scan).

[0205] To be eligible for this crossover, patients in Arm B must meet the following criteria: - Experienced radiological progression on control arm treatment with BICR as defined by RECIST 1.1 and PCWG3 of the protocol. -Has not started alternative anti-cancer therapy. · No ongoing uncontrolled toxicity. Adequate organ function independent of transfusion:

[0206] Bone marrow reserve: WBC count ≥ 2.5 × 109 / L or ANC ≥ 1.5 × 109 / L. Platelets ≥100×109 / L. Hemoglobin ≥ 5.6 g / dL.

[0207] Liver function: Total bilirubin ≤ 1.5 x institutional ULN. For patients with known Gilbert syndrome, ≤ 3 x ULN is acceptable. ALT or AST ≤ 3.0 × ULN.

[0208] Kidney function: Serum / plasma creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL / min. Albumin ≥ 30 g / L.

[0209] If patients are not eligible for crossover, they should instead complete the end-of-study visit and enter long-term follow-up.

[0210] 18 F-FDG PET (optional) 18F-FDG PET CT / MRI imaging will be performed at screening according to standard institutional procedures to assess the metabolic activity of detected lesions. This test is optional and will be performed at screening only for patients who consent to this additional testing.

[0211] PSMA-PET PSMA-PET imaging will be performed within 30 days of randomization, but after all other eligibility assessments have been performed.

[0212] PSMA imaging will be performed as coordinated by the investigator. 68 Ga-PSMA or 18 F-DCFPyL will be used. PET images will be reviewed centrally to identify sites of PSMA uptake and quantitate tracer uptake to determine eligibility and correlation with treatment response and / or progression.

[0213] High PSMA uptake as determined by central review was defined as follows: For patients with measurable disease (per RECIST 1.1 criteria), A threshold standardized uptake value (SUV) max of 15 or greater at one site of disease, and / or SUVmax >10 in all measurable disease areas. For patients without measurable disease, at least one positive lesion SUVmax >10 must be evident.

[0214] progress Radiological progression should be confirmed only by BICR. For patients showing signs of biochemical or clinical progression, every effort should be made to confirm this progression with CT / MRI and whole body bone scan. If discrepancies exist between the investigator and the central reader, the issue should be submitted to the medical monitor for resolution.

[0215] Patients in either group who discontinue due to progression will participate in a progression visit. If patients discontinue study treatment prior to the declaration of confirmed, BICR-assessed radiological progression, they should be followed for radiological progression by BICR and OS according to the SOA.

[0216] Patients in Arm B who have radiologically progressed by BICR will be evaluated and, if eligible, will be treated in cycle 1 of SOA 177 Crossover to give Lu-PSMA I&T.

[0217] Radiological progression Determination of radiological progression will be performed by BICR based on conventional imaging.

[0218] CT and MRI tumor evaluation CT or MRI images of the chest, abdomen, and pelvis will be used to assess progression according to PCWG3 modified RECIST 1.1 criteria, and other areas of disease will be investigated based on individual patient signs and symptoms. 177 All imaging performed after initiation of Lu-PSMA I&T (or control group) should include any suspicious sites of new disease. Nodal and visceral disease progression will be determined according to the PCWG3 modified RECIST 1.1 criteria of a ≥ 20% increase in target lesion SOD compared to the smallest total observed on study. Target lesion SOD must increase by at least 5 mm.

[0219] Bone scan Radiologic progression of bone disease is assessed by bone scintigraphy performed according to the institution's standard technique. Areas observed as positive on bone scan should be considered significant, and unequivocal areas of malignancy are recorded as metastatic bone lesions.

[0220] Progression of bone disease was determined according to the PCWG3 criteria of the appearance of two or more new bone lesions on the on-treatment scan and at least two additional new lesions on the next sequential scan (confirmatory scan).

[0221] biochemical progression Biochemical progression is determined as two consecutive increasing measurements of PSA above baseline taken 1 week apart according to PCWG3 criteria. PSA levels must be ≥ 2.0 ng / mL. Patients should not discontinue treatment due to biochemical progression. To prevent premature withdrawal from treatment phase, PSA results are not sent back to the site prior to interim or final analysis.

[0222] Clear clinical progression Clinical progression is 177 Lack of additional benefit to patients from Lu-PSMA I&T treatment or control treatment alone and one or more of the following: Initiation of chronic opioid use for new-onset prostate cancer pain suspected to be due to disease progression, defined as more than 7 consecutive days or more than 10 daily days within a 14-day period; or The urgent need to initiate cytotoxic chemotherapy for prostate cancer, or Deterioration of ECOG performance status to ≥ 3 due to prostate cancer, or Radiotherapy or surgical therapy for complications of prostate cancer tumor progression, excluding palliative radiotherapy (in the treatment of pain at the site of baseline present bone metastases, unless indicating disease progression); It is defined as:

[0223] Every attempt should be made to continue patients on study treatment until radiological progression by BICR has been declared.

[0224] Symptomatic skeletal-related events The occurrence of one or more of the following should be considered a symptomatic skeletal related event (SSRE): The use of radiation therapy to prevent or reduce bone symptoms. Incidence of a new symptomatic pathologic fracture (vertebral or non-vertebral). Radiologic documentation is required. Development of spinal cord compression. Radiological documentation is required. Orthopedic intervention for bone metastases.

[0225] PSA measurement and response Collection of blood samples for PSA assessment will occur during the treatment period.

[0226] Quantification of blood PSA levels will be performed by a central laboratory and results will be blinded to site.

[0227] A patient is considered to have a single PSA visit response if the PSA level at any post-dose visit declines by 50% or more compared to baseline.

[0228] A patient is considered to have a confirmed PSA response if they have a 50% or greater decrease in PSA levels compared to baseline that is confirmed at the next evaluation at least 3 weeks later (i.e., a decrease from baseline of at least 50% documented on two consecutive occasions separated by at least 3 weeks).

[0229] ECOG evaluation The investigator or his / her designee will assess the patient's performance status using the ECOG scale of performance status, which evaluates the patient's functioning in terms of ability for self-care, daily activities, and physical activity.

[0230] ECOG performance status grading 0 Fully active and able to maintain all pre-disease activities without limitation 1 Physically strenuous activity is limited, but walking is possible and light work or seated work, such as light housework and clerical work, is possible 2 Able to walk and perform all self-care activities, but unable to perform any occupational activities; able to walk and function vigorously for more than approximately 50% of the time 3 Limited self-care possible; spends more than 50% of waking hours in bed or chair 4 Completely disabled, unable to perform any self-care, confined to bed or chair 5 death

[0231] PSA response PSA response is defined as the proportion of patients achieving a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second serial PSA assessment at least 3 weeks later. Patients are considered to have a single PSA visit response if their PSA level at any post-dose visit has decreased by 50% or more compared to baseline. A patient is considered to have a confirmed PSA response if he or she has a decrease in PSA level of 50% or more compared to baseline that is confirmed at the next evaluation at least 3 weeks later (i.e., a decrease from baseline of at least 50% documented on two consecutive occasions separated by at least 3 weeks).

[0232] The numbers and percentages of PSA responders are presented by treatment group. The 95% confidence intervals for the difference in responder rates between the two treatment groups are displayed.

[0233] Biochemical progression-free survival Defined as the time from the date of randomization to the date of the first PSA increase of 25% or more from baseline and 2 ng / mL or more above nadir confirmed by a second PSA measurement defining progression at or after 3 weeks or death from any cause in the absence of progression according to PCWG3.

[0234] Patients who do not progress or die, including those who discontinued from the study or were lost to follow-up, will be censored at the date of their last valid PSA measurement from a scheduled or unscheduled visit.

[0235] bPFS is described using Kaplan-Meier estimates with 95% CI. Summary also includes numbers at risk, numbers of patients with an event, and numbers of patients censored.

[0236] Example 3: Preliminary Clinical Data SPLASH (NCT04647526) is a randomized controlled trial of 100 mg / kg / day ... 177 A multinational, phase III, open-label, randomized study to evaluate the efficacy and safety of Lu-PSMA I&T (177Lu-PNT2002). SPLASH is designed to evaluate radioligand therapy earlier in the treatment pathway, using fewer and lower doses compared to currently approved indications for radioligand therapy in prostate cancer. (i) SPLASH dosimetry results: The mean dose to red bone marrow was 0.034 Gy / GBq, which was well below the critical threshold, allowing potential opportunities for combination therapy. The organ receiving the highest absorbed dose was the lacrimal gland with 1.2 Gy / GBq, followed by the kidney with 0.73 Gy / GBq. (ii) Preliminary safety and efficacy results from the dosimetric run-in substudy of SPLASH: The SPLASH study began with a dosimetric and safety run-in phase of 27 participants before expanding randomization. See Figure 1. Participants were enrolled who had tumors with high PSMA uptake on PET / CT by blinded independent central review, had not received chemotherapy for CRPC, had progressed on ARPI, and had adequate bone marrow and end organ reserve. All participants received up to four cycles of 177Lu-PNT2002 at 6.8GBq per cycle every 8 weeks. See Figure 2. This dose was selected to minimize long-term risks while providing a dose found to be effective in previous trials with 177Lu-PSMA-I&T.

[0237] In the SPLASH lead-in cohort, the median rPFS duration was 11.5 months compared to a control arm benchmark of 3.5-4.2 months for similarly treated progressive mCRPC ARPI post-failure individuals. See Figure 3. Radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with evaluable disease at baseline. Figure 4 shows a vignette of a complete remission participant. The retroperitoneal lymph node target lesion (indicated by the white arrow) had a short-axis measurement of 2.1 cm at baseline, and complete remission of the lesion was demonstrated on imaging at month 11.

[0238] 177 Lu-PSMA I&T (177Lu-PNT2002) was well tolerated with no treatment-related deaths and few grade ≥3 treatment-related AEs. See Figure 5.

[0239] List of Abbreviations and Terms Used in the Examples 177Lu Lutetium-177 Androgen deprivation therapy (ADT) AE Adverse Event AESI Adverse events of particular interest ALP alkaline phosphatase ALT alanine aminotransferase ANC absolute neutrophil count AQA Analgesic Quantification Algorithm ARAT androgen receptor axis targeting ART radioactivity reference time AST Aspartate aminotransferase BICR blinded independent central review bPFS Biochemical progression-free survival BPI-SF Brief Pain Questionnaire-Short form CI confidence interval CMH Cochran-Mantel-Haenszel CR complete response CRPC (castration-resistant prostate cancer) CT computed tomography CTCAE Common Terminology Criteria for Adverse Events DCO interruption Duration of DOR response DMC Data Monitoring Committee DSMC Data Safety Monitoring Committee ECG Electrocardiography Eastern Cooperative Oncology Group (ECOG) eCRF Electronic Case Report Form EQ-5D-5L EuroQol 5-dimension 5-level health status utility index End of treatment FACT-P Functional Assessment of Cancer Therapy - Prostate Cancer Food and Drug Administration (FDA) FDG-PET Fluorodeoxyglucose-positron emission tomography GBq gigabecquerels GCP Good Clinical Practice Standards GCP II Glutamate Carboxypeptidase II GyGrey HDL high density lipoprotein HR hazard ratio HRQoL Health-related quality of life HSPC Hormone-Sensitive Prostate Cancer ICH International Conference on Harmonization of Pharmaceuticals for Human Use Institutional Review Board (IRB) ITT Intention to Treat IV Intravenous Infusion IVRS Interactive Voice Response System IWRS Web Automated Response System LDL low density lipoprotein LHRH Luteinizing hormone releasing hormone MBq megabecquerel MGy Mega Grey mCRPCMetastatic Castration-Resistant Prostate Cancer MRI Magnetic Resonance Imaging NAALADase I N-Acetyl-L-aspartyl-L-glutamic acid peptidase I OAEs and other adverse events ORR (Objective Response Rate) OS overall survival PARP poly ADP ribose polymerase PCA Prostate Cancer PCWG3 Prostate Cancer Working Group 3 PD progressive disease PET Positron Emission Tomography PFS Progression-free survival PK Pharmacokinetics PP Per Protocol PR partial response PSA (prostate-specific antigen) PSMA prostate-specific membrane antigen rPFSRadiation-free survival QoLQuality of Life REB Research Ethics Committee RECIST solid tumor response criteria SAEs Serious Adverse Events SAP Statistical Analysis Planning SD steady state SOA Activity Schedule SOC standard treatment Total SOD diameter SSRE Symptomatic Bone-Related Events SOP Standard Operating Procedure SPECT single photon emission computed tomography SUV standard intake value TOC Calibration Time ULN normal upper limit USPI United States Package Insert WBC white blood cell count

[0240] Example References 1.Tannock IF, de Wit R, Berry WR, et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med.2004;351(15):1502-1512. 2. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2016. Toronto, ON: Canadian Cancer Society; 2016. 3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30. 4. Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One.2015;10(10):e0139440. Published October 13, 2015. 5. Smith MR, Saad F, Chowdhury S, et al.Apalutamide treatment and metastasis-free survival in prostate cancer.N Engl J Med.2018;378(15):1408-1418. 6.Fizazi K,Shore N,Tammela TL,et al.Darolutamide in nonmetastatic,castrationresistant prostate cancer.N Engl J Med.2019;380(13):1235-1246。 7.de Bono JS,Logothetis CJ,Molina A,et al.Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med.2011;364(21):1995-2005。 8.Ryan CJ,Smith MR,Fizazi K,et al.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer(COU-AA-302):final overall survival analysis of a randomized,double-blind,placebo-controlled phase 3 study.Lancet Oncol.2015;16():152-160。 9.Scher HI,Fizazi K,Saad F,et al.Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med.2012;367(13):1187-1197。 10.Fizazi K,Scher HI,Molina A,et al.Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301 randomised,double-blind,placebo-controlled phase 3 study.Lancet Oncol.2012;13(10):983-992。 11.Shivji A,Ali R,North S,Sawyer M,Ghosh S,Chambers C.Real world evidence:Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.J Oncol Pharm Pract.2019;25(6):1293-1300。 12.Ryan CJ,Smith MR,de Bono JS,et al.Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med.2013;368(2):138-148。 13.Beer TM,Armstrong AJ,Rathkopf DE,et al.Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med.2014;317:424-433。 14.Bauman G,Charette M,Reid R,Sathya J.Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.Radiother Oncol.2005;75(3):258-270。 15.Parker C,Nilsson S,Heinrich D,et al.Alpha emitter radium-223 and survival in metastatic prostate cancer.N Engl J Med.2013;369(3):213-223。 16.Silver DA,Pellicer I,Fair WR,Heston WD,Cordon-Cardo C.Prostate-specific membrane antigen expression in normal and malignant human tissues.Clin Cancer Res.1997;3(1):81-85。 17.Kasperzyk JL,Finn SP,Flavin R,et al.Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.Cancer Epidemiol Biomarkers Prev.2013;22(12):2354-2363。 18.Meller B,Bremmer F,Sahlmann CO,et al.Alterations in androgen deprivation enhanced prostate-specific membrane antigen(PSMA)expression in prostate cancer cells as a target for diagnostics and therapy.EJNMMI Res.2015;5(1):66. 19.Tasch J,Gong M,Sadelain M,Heston WD.A unique folate hydrolase,prostate-specific membrane antigen(PSMA):a target for immunotherapy Crit Rev Immunol.2001;21(1-3):249-261。 20.Sokoloff MH,Yang XJ,Fumo M,Mhoon D,Brendler CB.Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of<4.0ng / mL.BJU Int.2004;93(4):499-502。 21.Hillier SM,Maresca KP,Femia FJ,et al.Preclinical evaluation of novel glutamate-urealysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.Cancer Res.2009;69(17):6932-6940。 22.Chen Y,Pullambhatla M,Foss CA,et al.2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid,[18F]DCFPyL,a PSMA-based PET imaging agent for prostate cancer.Clin Cancer Res.2011;17(24):7645-7653。 23.Afshar-Oromieh A,Haberkorn U,Eder M,Eisenhut M,Zechmann CM.[68Ga]Galliumlabelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer:comparison with 18F-FECH.Eur J Nucl Med Mol Imaging.2012;39(6):1085-1086。 24.Maurer T,Gschwend JE,Rauscher I,et al.Diagnostic efficacy of(68)gallium-PSMA Positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer.J Urol.2016;195(5):1436-1443。 25.Perera M,Papa N,Christidis D,et al.Sensitivity,specificity,and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer:a systematic review and meta-analysis.Eur Urol.2016;70(6):926-937。 26.Eiber M,Maurer T,Souvatzoglou M,et al.Evaluation of hybrid 68Ga-PSMA ligand PET / CT in 248 patients with biochemical recurrence after radical prostatectomy.J Nucl Med.2015;56(5):668-674。 27.Dietlein M,Kobe C,Kuhnert G,et al.Comparison of[(18)F]DCFPyL and[(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer.Mol Imaging Biol.2015;17(4):575-584。 28.Ferreira G,Iravani A,Hofman MS,Hicks RJ.Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution.Cancer Imaging.2019;19(1):23. 29.Giesel FL,Will L,Lawal I,et al.Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET / CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma:a pilot study.J Nucl Med.2018;59(7):1076-1080。 30.Bander NH,Milowsky MI,Nanus DM,Kostakoglu L,Vallabhajosula S,Goldsmith SJ.Phase I trial of 177lutetium-labeled J591,a monoclonal antibody to prostate-specific membrane antigen,in patients with androgen-independent prostate cancer.J Clin Oncol.2005;23(21):4591-4601。 31.Tagawa ST,Milowsky MI,Morris M,et al.Phase II study of Lutetium-177-labeled antiprostate-specific membrane antigen monoclonal antibody J591 for metastatic castrationresistant prostate cancer.Clin Cancer Res.2013;19(18):5182-5191。 32.Benesova M,Schafer M,Bauder-Wust U,et al.Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer.J Nucl Med.2015;56(6):914-920。 33.Kratochwil C,Giesel FL,Eder M,et al.[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.Eur J Nucl Med Mol Imaging.2015;42(6):987-988。 34.Schlenkhoff CD,Knupfer E,Essler M,Ahmadzadehfar H.Metastatic prostate cancer with restored hormone-response after radioligand therapy with 177Lu-PSMA-617.Clin Nucl Med.2016;41(7):572-573。 35.Roll W,Bode A,Weckesser M,Bogemann M,Rahbar K.Excellent response to 177Lu-PSMA-617radioligand therapy in a patient with advanced metastatic castration resistant prostate cancer evaluated by 68Ga-PSMA PET / CT.Clin Nucl Med.2017;42(2):152-153。 36.Ahmadzadehfar H,Eppard E,Kurpig S,et al.Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.Oncotarget.2016;7(11):12477-12488。 37.Kratochwil C,Giesel FL,Stefanova M,et al.PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617.J Nucl Med.2016;57(8):1170-1176。 38.Rahbar K,Bode A,Weckesser M,et al.Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer.Clin Nucl Med.2016;41(7):522-528。 39.Rahbar K,Schmidt M,Heinzel A,et al.Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer:a multicenter retrospective analysis.J Nucl Med.2016;57(9):1334-1338。 40.Fendler WP,Reinhardt S,Ilhan H,et al.Preliminary experience with dosimetry,response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration resistant prostate cancer.Oncotarget.2017;8(2):3581-3590。 41.Rahbar K,Ahmadzadehfar H,Kratochwil C,et al.German multicenter study investigating 177Lu-PSMA-617radioligand therapy in advanced prostate cancer patients.J Nucl Med.2017;58(1):85-90。 42.Weineisen M,Simecek J,Schottelius M,Schwaiger M,Wester HJ.Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.EJNMMI Res.2014;4(1):63. 43.Weineisen M,Schottelius M,Simecek J,et al.68Ga-and 177Lu-labeled PSMA I&T:optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies.J Nucl Med.2015;56(8):1169-1176。 44.Heck MM,Retz M,D’Alessandria C,et al.Systemic radioligand therapy with(177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer.J Urol.2016;196(2):382-391。 45.Heck MM,Tauber M,Schwaiger S,et al.Treatment outcome,toxicity,and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer.Eur Urol.2019;75(6):920-926。 46.Baum RP,Kulkarni HR,Schuchardt C,et al.177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer:safety and efficacy.J Nucl Med.2016;57(7):1006-1013。 47.Kulkarni H,Schuchardt C,Singh A,Langbein T,Baum R.Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer.J Nucl Med.2018;59(suppl 1):529. 48.Acar E,Ozdogan O,Aksu A,Derebek E,Bekis R,Capa Kaya G.The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival.Ann Nucl Med.2019;33(9):681-688。 49.Yamoah K,Showalter TN,Ohri N.Radiation therapy intensification for solid tumors:a systematic review of randomized trials.Int J Radiat Oncol Biol Phys.2015;93(4):737-745。 50.Marin G,Vanderlinden B,Karfis I,et al.Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy.EJNMMI Phys.2017;4(1):7. 51.Chung DY,Kang DH,Kim JW,et al.Comparison of oncologic outcomes between two alternative sequences with abiraterone acetate and enzalutamide in patients with metastatic castration-resistant prostate cancer:a systematic review and meta-analysis.Cancers(Basel).2019;12(1):8. 52.De Bono J,Mateo J,Fizazi K,et al.Olaparib for metastatic castration-resistant prostate cancer.N Engl J Med.2020;382(22):2091-2102。 53.Lorente D,Omlin A,Ferraldeschi R,et al.Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.Br J Cancer.2014;111(12):2248-2253。 54.Okamoto S,Thieme A,Allman J,et al.Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer:absorbed dose in normal organs and tumor lesions.J Nucl Med.2017;58(3):445-450。 55.Dawson LA,Kavanagh BD,Paulino AC,et al.Radiation-associated kidney injury.Int J Radiat Oncol Biol Phys.2010;76(3 Suppl):S108-S115。 56.Emami B,Lyman J,Brown A,et al.Tolerance of normal tissue to therapeutic irradiation.Int J Radiat Oncol Biol Phys.1991;21(1):109-122。 57.Wu VWC,Leung KY.A review on the assessment of radiation induced salivary gland damage after radiotherapy.Front Oncol.2019;9:1090。 58.Kesavan M,Turner JH,Meyrick D,Yeo S,Cardaci G,Lenzo NP.Salvage therapy of advanced castrate-resistant prostate cancer with lutetium-177-labeled prostate-specific membrane antigen:efficacy and safety in routine practice.Cancer Biother Radiopharm.2018;33(7):274-281。 59.Gafita A,Kroenke M,Tauber R,Weber W,Eiber M.Correlation of 12-week PSA response after 177Lu-PDMA radioligand therapy,baseline tumor burden and overall survival in mCRPC.J Nucl Med.2019;60:78。 60.Siegel JA,Thomas SR,Stubbs JB,Stabin MG,Hays MT,Koral KF,et al.MIRD pamphlet no.16:Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.J Nucl Med.1999 Feb;40(2):37S-61S。 61.Siegel JA.Establishing a Clinically Meaningful Predictive Model of Hematologic Toxicity in Nonmyeloablative Targeted Radiotherapy:Practical Aspects and Limitations of Red Marrow Dosimetry.Cancer Biotherapy & Radiopharmaceuticals.2005;20(2):126-140。 62.Ferrer L,Kraeber-BodereF,Bodet-Milin C,et al.Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.Cancer.2010;116(4 Suppl):1093-100。 63.Forrer F,Krenning EP,Kooij PP,et al.Bone marrow dosimetry in peptide receptor radionuclide therapy with[177Lu-DOTA(0),Tyr(3)]octreotate.Eur J Nucl Med Mol Imaging.2009;36(7):1138-46。 64.Herrmann K,Bluemel C,Weineisen M et al.Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.J Nucl Med.2015;56(6):855-61。 65.Sgouros G.Bone marrow dosimetry for radioimmunotherapy:theoretical considerations.J Nucl Med.1993;34:689-94。 66.Stabin MG,Sparks RB,Crowe EB.OLINDA / EXM-The Second Generation Personal Computer Software For Internal Dose Assessment In Nuclear Medicine.J Nucl Med.2005;(46):1023-1027。 67.Stabin M,Farmer A.OLINDA / EXM 2.0:The new generation dosimetry modeling code.J Nucl Med.2012;53(suppl 1):585。 68.Thang SP,Violet J,Sandhu S,et al.Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen(PSMA)Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.Eur Urol Oncol.2019;2(6):670-676。 69.Emmett L,Crumbaker M,Ho B,et al.Results of a Prospective Phase II Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.Clin Genitourin Cancer.2019;17(1):15-22。 70.Hofman MS,Emmet L,Violet J et al.TheraP:a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castrationresistant prostate cancer(Clinical Trial Protocol ANZUP 1603).BJU Int.2019;124(Supplement 1):5-13。 71.Buckley O,O’Keffe S,Geoghegan T,et al.99mTc bone scintigraphy superscans:a review.Nucl Med Commun.2007;28(7)521-527。 72.Scher HI,Morris MJ,Stadler WM,et al.Trial design and objectives for castration resistant prostate cancer:updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.J Clin Oncol.2016;34(12):1402-1418。 73.Shen S,DeNardo GL,Sgouros G,O’Donnell RT,DeNardo SJ.Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.J Nucl Med.1999;40(12):2102-2106。 74.de Wit R, de Bono J, Sternberg CN, et al.Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.N Engl J Med.2019;381(26):2506-2518. 75.FDA guidance on Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.Available from https: / / www.fda.gov / downloads / Drugs / Guidances / ucm071590.pdf. 76. Chung KC, Barlev A, Braun AH, et al. Assessing analgesic use in patients with advanced cancer: development of a new scale-the Analgesic Quantification Algorithm. Pain Medicine.2014;15:225-232. 77.Erwin WA novel heart-contents image-based Yttrium-90-Zevalin red marrow residence time estimator.JNM May 2010,51(supplement 2)1323.

[0241] Incorporation by Reference The entire contents of all patents, published patent applications, websites, and other disclosures cited herein are expressly incorporated herein by reference in their entirety.

Claims

1. 1. A method for treating a subject suffering from prostate cancer, comprising: a) identifying subjects who: i) exhibit prostate cancer progression during or after treatment with one or more androgen receptor inhibitors, and ii) have not received chemotherapy prior to said treatment with one or more androgen receptor inhibitors; and b) administering to said identified subject an amount of a lutetium-177 labeled PSMA targeted radioligand agent providing a dose of 4-10 Gbq, said subject receiving at least four doses of said lutetium-177 labeled PSMA targeted radioligand agent with an inter-dosing interval of four weeks or longer.

2. 2. The method of claim 1, wherein said lutetium-177 labeled PSMA targeted radioligand agent is a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

3. 3. The method of claim 1 or 2, wherein the subject has demonstrated cancer progression during treatment with one or more of abitaterone, enzalutamide, apalutamide, darolutamide, cimetidine, orteronel, galeterone, ceviteronel, topirutamide, bicalutamide, fluamide, and / or nilutamide.

4. 3. The method of claim 1 or 2, wherein the subject has demonstrated cancer progression during treatment with one or more of abitaterone, enzalutamide, apalutamide, and / or darolutamide.

5. 3. The method of claim 1 or 2, wherein the subject has demonstrated cancer progression during treatment with one or more of abitaterone, apalutamide, and / or darolutamide.

6. 6. The method of any one of claims 1 to 5, wherein the subject exhibits cancer progression at least one month after treatment with one or more androgen receptor inhibitors.

7. The method of any one of claims 1 to 6, wherein the treatment with one or more androgen receptor inhibitors is the only chemotherapy administered to the subject prior to administration of the lutetium-177 labeled PSMA-targeted radioligand.

8. The method of any one of claims 1 to 7, wherein the subject is taxane chemotherapy naive and / or taxane chemotherapy is harmful.

9. The method of any one of claims 1 to 8, wherein the identified subject exhibits elevated PSMA expression compared to healthy subjects.

10. The method of any one of claims 1 to 9, wherein the subject is identified by imaging PSMA expression of the cancer.

11. The method of any one of claims 1 to 10, wherein the identified subject exhibits a PSMA expression standardized uptake value (SUV)max of 15 or greater at one site of disease and / or an SUVmax of greater than 10 at all measurable sites of disease.

12. The method of any one of claims 1 to 11, wherein the identified subjects exhibit at least one positive lesion SUVmax greater than 10.

13. The method of any one of claims 1 to 12, wherein the identified subject exhibits an elevated PSA level.

14. The method of any one of claims 1 to 13, wherein the subject is identified based on radiological assessment of cancer progression during treatment with one or more androgen receptor inhibitors.

15. The method of any one of claims 1 to 14, wherein the subject is identified based on an elevated PSA level.

16. 16. The method of any one of claims 1 to 15, wherein the administration of one or more androgen receptor inhibitors is terminated prior to administering the complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

17. The method of any one of claims 1 to 16, wherein the subject is afflicted with a cancer that expresses PSMA.

18. The method of any one of claims 1 to 16, wherein the subject is suffering from prostate cancer.

19. The method of any one of claims 1 to 16, wherein the subject is afflicted with metastatic castration-resistant prostate cancer (mCRPC).

20. The method according to any one of claims 1 to 16, wherein the subject is suffering from metastatic castration-resistant prostate cancer (mCRPC) with prostate-specific membrane antigen (PSMA)-high accumulation lesions.

21. 21. The method of any one of claims 1 to 20, wherein the complex of Lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA is administered in combination with one or more separate chemotherapeutic agents.

22. The complex of lutetium-177 with EuK-Sub-kf-Iodo-y-DOTAGA has the following structure: [Formula 1] The method according to any one of claims 1 to 21, comprising:

23. The method of any one of claims 1 to 22, wherein the subject is a human.

24. For treating a subject suffering from prostate cancer, 177 1. Use of Lu-PSMA I&T comprising: a) identifying a subject exhibiting progression of prostate cancer during treatment with one or more androgen receptor inhibitors; and b) administering to the identified subject an effective amount of 177 and administering Lu-PSMA I&T.

25. For treating a subject suffering from cancer, 177 16. Use of Lu-PSMA I&T, comprising: a) administering to said subject a therapeutically effective amount of one or more androgen receptor inhibitors; b) identifying said subject as exhibiting cancer progression after administration of said one or more androgen reception inhibitors; and then c) administering to said identified subject an effective amount of 177 and administering Lu-PSMA I&T.

26. A kit comprising: a pharmaceutical preparation of a lutetium-177 labeled PSMA targeted radioligand agent suitable for intravenous administration to a subject, in an amount sufficient to provide a dose of 4-10 Gbq; and a package insert containing instructions for use of the radioligand agent in the treatment of a subject exhibiting prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has previously been treated with androgen receptor (AR) pathway inhibition but has not received taxane chemotherapy or for whom taxane chemotherapy is harmful.

27. 27. The kit of claim 26, wherein the instructions on the package insert include guidance for administering the lutetium-177 labeled PSMA targeted radioligand therapy to a patient at least four times and with an inter-dosing interval of four weeks or longer.

28. The kit of claim 26 or 27, wherein the package insert further comprises an indication that the shelf life of the lutetium-177 labeled PSMA targeted radioligand is 120 hours from completion of synthesis and formulation of the pharmaceutical preparation of the lutetium-177 labeled PSMA targeted radioligand for use in the kit.

29. The kit of any one of claims 26 to 28, wherein the package insert further comprises instructions for selecting a patient / animal using the PSMA targeted imaging agent.

30. 30. The kit of any one of claims 26 to 29, wherein the package insert further comprises instructions for ensuring that the patient increases their oral fluid intake and advising the patient to urinate as frequently as possible to reduce bladder radiation exposure.

31. The kit of any one of claims 26 to 30, wherein the lutetium-177 labeled PSMA targeted radioligand agent is a complex of lutetium-177 and EuK-Sub-kf-Iodo-y-DOTAGA.

32. 32. The kit of claim 31, wherein the lutetium-177 EuK-Sub-kf-Iodo-y-DOTAGA complex is provided in a single dosage form sufficient to provide 6.8 GBq + / - 10% within the effective period.

33. 33. The kit of claim 31 or 32, wherein the package insert further comprises instructions for administering the Lutetium-177 EuK-Sub-kf-Iodo-y-DOTAGA complex to the patient up to four times, with an interval of eight weeks between each administration.

34. 34. The kit of any one of claims 31 to 33, wherein the pharmaceutical preparation comprises sodium ascorbate in a concentration of 55 to 75 mg / mL and sodium gentisate in a concentration of 16 to 36 mg / mL and has a pH in the range of 5.0 to 7.

0.

35. 35. The kit of any one of claims 31 to 34, wherein the pharmaceutical preparation has a radioactivity concentration (RAC) of 0.5 to 1.2 GBq / mL, more preferably 0.79 to 0.86 GBq / mL ± 10%, at the end of synthesis and formulation of the pharmaceutical preparation.

36. 36. The kit according to any one of claims 31 to 35, wherein the pharmaceutical preparation has a total peptide content of 250 μg or less (EuK-Sub-kf-Iodo-y-DOTAGA and Lutetium-177 EuK-Sub-kf-Iodo-y-DOTAGA complex combined), preferably in the range of 180 to 250 μg.

37. 37. The kit of any one of claims 26 to 36, wherein the pharmaceutical preparation is provided in a single dose vial, the kit optionally further comprising a disposable syringe with a syringe shield for handheld injection administration.

38. The kit of any one of claims 26 to 36, wherein the pharmaceutical preparation is provided in a disposable syringe with a syringe shield for handheld injection administration.

39. The kit of any one of claims 26 to 38, wherein the kit comprises a radiation shielded bulk metal container in which the pharmaceutical preparation is shipped in the packaged kit.

40. The package insert complies with the following criteria: a) serum / plasma PSA progression, defined as an increase in PSA above nadir of more than 25% and more than 2 ng / mL; b) Progression on one prior ARAT therapy in either the CSPC or CRPC setting; c) PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) positive; d) castrate circulating testosterone levels (<1.7 nmol / L or <50 ng / dL); and / or e) Adequate bone marrow, kidney, and liver organ function 40. The kit of any one of claims 26-39, further comprising instructions for patient / patient eligibility, including that the patient must have progressive mCRPC at the time of consent, based on one or more of:

41. 41. The kit of claim 40, wherein the package insert includes instructions for patient / patient eligibility based on each of the criteria a), b), c), d), and e), where the patient / patient must have progressive mCRPC at the time of consent.

Citation Information

Patent Citations

  • Radiopharmaceutical and methods

    US11129912B1